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AGE-RELATED MACULAR DEGENERATION 
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ABSTRACT 
        The goal of this thesis research was to develop methods to predict susceptibility to 
age-related macular degeneration (AMD). Age-related macular degeneration (AMD) is 
the most common cause of legal blindness in the elderly in developed countries, and 
early identification of susceptibility is important for preventing this progressive disease. 
New and original evidence was found supporting the prognostic potential of plasma 
advanced glycation endproducts (AGEs) as possible biomarkers for AMD, specifically 
the oxidative protein modifications Nε-(carboxymethyl)lysine (CML) and pentosidine. 
Quantitative analyses of plasma from AMD (n = 60) and normal control (n = 30) donors 
showed that mean CML and pentosidine levels were elevated in AMD plasma by ~ 60% 
and ~ 80%, respectively, while furosine was largely unchanged. Another type of 
oxidative modification, carboxyethylpyrrole (CEP) adducts, were found to be ~ 2-fold 
higher in AMD (n = 56) than in controls (n = 30), consistent with previous findings. C-
statistics were determined from receiver operating characteristic curves that indicate for 
these plasma samples, CML discriminated between AMD and control donors with ~ 80% 
accuracy, CEP adducts with ~ 81% and pentosidine with ~ 92% accuracy. In 
combination with CEP, CML provided ~ 89% accuracy and pentosidine provided ~ 95% 
discrimination accuracy. Overall, these results provided evidence that CML and 
pentosidine are both elevated in AMD plasma and may prove useful for predicting AMD 
susceptibility and for monitoring AMD therapeutics, especially in combination with CEP 
biomarkers. 
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CHAPTER I 
INTRODUCTION 
 
 
 
1.1 The Human Eye 
          The eye is a highly specialized organ of photoreception (Figure 1.1). The 
process of vision formation is initiated when light energy from the environment 
produces changes in specialized nerve cells in the retina, the rods and cones. 
These changes result in nerve action potentials, which are subsequently relayed 
to the optic nerve and then to the brain, where the information is processed and 
consciously appreciated as vision. All the other structures in the eye are 
secondary to this basic physiologic process, although they may be part of the 
system necessary for focusing and transmitting the light to the retina, for example 
the cornea, lens and iris, or they may be necessary for nourishing and supporting 
the tissues of the eye, for example the choroid, aqueous outflow system, and 
lacrimal apparatus. 
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Figure 1.1. Schematic Diagram of The Human Eye. 
(1) Iris, the colored part of the eye that regulates the amount of light entering 
the eye; (2) Cornea, the clear outer part of the eye’s focusing system located 
at the front of the eye; (3) Pupil, the opening at the center of the iris, its size is 
adjusted by the iris to control the amount of light that can enter the eye; (4) 
Lens, a clear part of the eye behind the iris that helps to focus light, or an 
image, on the retina; (5) Vitreous gel, a clear gel that fills the inside of the eye; 
(6) Optic nerve, a bundle of more than one million nerve fibers that carries 
visual messages from the retina to the brain; (7) Macula, the small sensitive 
area of the retina that gives central vision. It is located in the center of the 
retina and contains the fovea; (8) Fovea, the center of the macula and gives 
the sharpest vision; (9) Retina, the light-sensitive tissue lining at the back of 
the eye, which can convert light into electrical impulses that are sent to the 
brain through the optic nerve. The figure and information are provided by the 
National Eye Institute (NEI). 
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1.2 Retina 
          The retina is a multi-layered sensory tissue that is bound externally by 
Bruch’s membrane and on its internal aspect by the vitreous at the back of the 
eye. It contains millions of photoreceptors that capture light and convert photons 
into electrical impulses. These impulses travel along the optic nerve to the brain 
where they are converted into images. The retina consists of two primary layers: 
an inner neurosensory retina and an outer epithelium, the retinal pigment 
epithelium (RPE). Between the neurosensory retina and RPE is a potential space, 
the subretinal space, across which the two layers must adhere (Forrester et al., 
1996). 
 
1.2.1 The Retina  
          The neurosensory retina is a thin transparent layer of neural tissue 
composed of inner and outer layers and several different cell types (Figure 1.2). 
The outer neurosensory retina is composed of photoreceptor cells (i.e. rods and 
cones). The inner neurosensory retina is composed of other cell types, including 
Müller cells, ganglion cells, bipolar cells, horizontal cells, amacrine cells and 
other non-neuronal cells. Photoreceptor cells, ganglion cells and bipolar cells are 
the three principle neuronal cell types for signal relay. Horizontal cells, amacrine 
cells and other non-neuronal cells modulate the activity of the principle neuronal 
cells.  
          Retinal cells are arranged in a highly organized manner, and in histological 
sections appear as ten distinct layers shown in Figure 1.2. The first layer, the 
 4 
 
inner limiting membrane (ILM), a boundary between the vitreous humor in the 
posterior chamber and the retina itself, is formed by astrocytes and the end feet 
of the Müller cells. The nerve fiber layer (NFL) is formed by the expansion of the 
fibers of the optic nerve. The ganglion cell layer (GCL) contains the cell bodies 
and axons of ganglion cells. The synaptic junctions of bipolar, amacrine and 
ganglion cells form the inner plexiform layer (IPL). Primates possess a thinner 
IPL than non-primates. The thicker IPL indicates that these retinas perform more 
peripheral and different image processing than in primates. The inner nuclear 
layer (INL) contains nuclear bodies of bipolar cell, horizontal, and amacrine cell 
bodies. The outer plexiform layer (OPL) contains the synaptic junctions of bipolar 
cells and horizontal cells. The nuclei of photoreceptor cells, rod and cone cells, 
form the outer nuclear layer (ONL). The outer limiting membrane (OLM) is the 
layer that separates the inner segment portions of the photoreceptors from their 
cell nuclei and a network where Müller cells contact the photoreceptor cell nuclei. 
The photoreceptor outer segments (POS) with the rod and cone cells extend 
beyond the ONL to the retinal pigment epithelium (RPE) (Forrester et al., 1996). 
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Figure 1.2. Structure Arrangement of Retina. (A) Methylene blue stained 
semi-thin section of guinea pig retina showing the structural arrangement of 
neuronal and plexiform layers. (B) Schematic diagram of retinal connections, 
including ten layers (from inner to outer): (1) ILM, inner limiting membrane; (2) 
NFL, nerve fiber layer; (3) GCL, ganglion cell layer; (4) IPL, inner plexiform 
layer; (5) INL, inner nuclear layer; (6) OPL, outer plexiform layer; (7) ONL, 
outer nuclear layer; (8) OLM, outer limiting membrane; (9) POS, photoreceptor 
outer segments; (10) RPE, retinal pigment epithelium. Six major cell types: 
photoreceptor cell (cone and rod); GC, ganglion cell; AC, amacrine cell; BC, 
bipolar cell; HC, horizontal cell; MC, Müller cell. Figure is obtained form 
http://www.anatomy.unimelb.edu.au/researchlabs/rees/projects.html. 
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1.2.2 Structure and Function of Photoreceptor Cells 
          Photoreceptor cells are specialized types of neurons found in the retina 
that initiate phototransduction by converting light (electromagnetic radiation) into 
a chain of biological processes. More specifically, the photoreceptor absorbs 
photons, and through specific and complex biochemical pathways, initiates 
electrochemical signals through changes in its membrane potential.  
          Three types of photoreceptor cells are found in vertebrate retina. The two 
classic photoreceptors are rods and cones (Figure 1.3), each contributing 
information used by the visual system to form a representation of the visual world, 
sight. They are situated in the outer retina. The novel third photoreceptor is a 
recently discovered class of photosensitive ganglion cells. These cells, found in 
the inner retina, have dendrites and long axons projecting to the pretectum 
(midbrain). Unlike other retinal ganglion cells, these photosensitive ganglion cells 
are intrinsically photosensitive, which means that they can be excited by light 
even when all influences from classical photoreceptors (rods and cones) are 
blocked (Forrester et al., 1996). 
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Figure 1.3. Schematic Diagram of Two Primary Types of Photoreceptor 
Cells. Rod (left) and cone (right) photoreceptors have the same basic 
structure. The cells are divided into two sections. The bottom portion is called 
the inner segment. It contains the nucleus and the synaptic ending. The 
synaptic ending attaches to the neurons which produce signals that go to the 
brain. The top portion is called the outer segment. The outer segment is 
comprised of a membrane which is folded into several layers of disks. The 
disks are comprised of cells that contain the molecules that absorb the light 
(Reproduced from Young et al., 1970). 
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          Light initiates the phototransduction cascade and the retinoid visual cycle 
by isomerization of 11-cis-retinaldehyde bound to the visual pigment proteins in 
the rod and cone photoreceptor cells. Each photoreceptor cell is composed of an 
outer and inner segment. The outer segment contains the visual pigments and is 
in contact with the RPE cells. In contrast, the inner segment is important for cell 
metabolism and synapse with the bipolar and horizontal cells in the retina. The 
bipolar cells are vertically oriented and synapse between the photoreceptor cells 
and the ganglion and amacrine cells. The axons of the ganglion cells form the 
retinal unmyelinated nerve fiber layer and eventually the axons of the optic nerve. 
The horizontal and amacrine cells contain short axons and function to modulate 
and transform visual information at short distances. The main glial cell of the 
retina is the Müller cell, which provides structural support and nutrition for the 
retina and is thought to participate in the regeneration of cone visual pigments 
(cone visual cycle). The vascular supply for the inner retina is from the central 
retinal artery and for the outer retina from the choroidal circulation. 
          There are approximately 115 million rods and 6.5 million cones in the 
human eye. Rods are responsible for sensing contrast, brightness, and motion, 
while cones subserve fine resolution, spatial resolution, and color vision. The 
density of rods and cones varies in different regions of the retina, the periphery 
being rod-dominated (30,000 per mm2) while cone density increases nearer the 
macula (150,000 per mm2 at the fovea), the fovea being exclusively cones 
(Forrester et al., 1996).  
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1.2.3 Retinal Pigment Epithelium (RPE)  
          The RPE is a continuous monolayer of pigmented epithelial cells between 
the neural retina and Bruch’s membrane. RPE cells vary in size and shape 
depending on age and location. The basal membrane of RPE cells is in contact 
with Bruch’s membrane, a multilayered extracellular matrix that separates the 
RPE from the underlying choriocapillaris. The apical side of the RPE associates 
with the tips of the outer segments of photoreceptor cells. RPE cells form a highly 
organized hexagonal pattern of cells (Figure 1.4) with the number of cells varying 
from 4.2 to 6.1 million (Forrester et al., 1996).  
          The RPE has many physical, optical, metabolic/biochemical and transport 
functions and plays a critical role in normal visual processes (Figure 1.4). The 
pigmented cells in the RPE absorb scattered light (Bok et al., 1993; Boulton et al., 
2001a) and support the survival and normal functioning of photoreceptors by 
acting as the outer blood-retinal barrier to control exchange between the 
underlying choroidal blood vessels and overlying photoreceptors (Ban et al., 
2000; McBee et al., 2001). The RPE transports ions, water, and metabolic end 
products from the subretinal space to the blood (Miller et al., 1990; Dornonville et 
al., 1993; Marmor et al., 1999; Hamann et al., 2000). It also takes up nutrients 
such as glucose, retinol, and fatty acids from the blood and delivers these 
nutrients to photoreceptors.  
          Importantly, retinoid is constantly exchanged between photoreceptors and 
the RPE (Baehr et al., 2003; Besch et al., 2003; Thompson et al., 2003) because 
the photoreceptors are unable to isomerize all-trans-retinaldehyde, formed after 
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photon absorption and isomerization of 11-cis-retinaldehyde. The RPE 
enzymatically converts all-trans-retinaldehyde to 11-cis-retinaldehyde, a process 
known as the rod visual cycle. The voltage-dependent ion conductance of the 
apical membrane enables the RPE to stabilize the ion composition in the 
subretinal space, which is essential for the maintenance of photoreceptor 
excitability (Steinberg et al., 1983; Steinberg et al., 1985). Another RPE function 
in the maintenance of photoreceptor health is the phagocytosis of photoreceptor 
outer segments (Bok et al., 1993; Strauss et al., 1998; Gal et al., 2000; 
Finnemann et al., 2003). The shed photoreceptor outer segments are digested in 
the RPE, and essential substances such as retinaldehyde are recycled and 
returned to the photoreceptors to rebuild light-sensitive outer segments. In 
addition, the RPE is able to secrete a variety of growth factors that help maintain 
the structural integrity of the choriocapillaris endothelium and photoreceptors 
(Strauss et al., 2005). Furthermore, the secretory activity of the RPE plays an 
important role in establishing the immune privilege of the eye by secreting 
immunosuppressive factors (Streilein et al., 2002; Ishida et al., 2003). With these 
complex, different functions, the RPE is essential for visual function. A failure of 
any one of these functions can lead to degeneration of the retina, loss of visual 
function, and blindness. 
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1.3 Age-related Macular Degeneration (AMD) 
          Age-related macular degeneration (AMD) is a progressive 
neurodegenerative disease of the central retina, and represents the most 
common cause of legal blindness in industrialized countries (Klaver et al., 1998). 
It is a leading cause of vision loss in Americans 60 years of age and older. About 
9 million individuals in the United States have AMD, and about 3 million 
Americans are at high risk of developing AMD (Friedman et al., 2004). Age-
related macular degeneration (AMD) gradually destroys sharp, central vision, 
Figure 1.4. Summary of Retinal Pigment Epithelium (RPE) Functions. The 
RPE is a monolayer of pigmented cells forming a part of the blood/retina 
barrier. It plays an important role in the normal visual process with the function 
of light absorption, protection against photo-oxidation, transepithelial 
transportation of nutrients and ions, spatial buffering of ions in the subretinal 
space, photoreceptor outer segment phagocytosis and secretion. (Reproduced 
from Strauss et al., 2005). 
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because of the degradation of macula (Figure 1.5), the central part of the retina 
that provides high acuity vision (Bird et al., 1995; de Jong et al., 2006).  
 
1.3.1 Classification  
          Based on criteria proposed by the Age-Related Eye Disease Study 
(AREDS) (Age-Related Eye Disease Study Group, 2000; Jager et al., 2008), the 
stages of AMD disease progression are categorized by the size and extent of 
drusen (deposition of extracellular debris on Bruch’s membrane), the 
manifestations of geographic atrophy and neovascular changes (Figure 1.6). 
Early AMD (AREDS category 2) is characterized by the presence of less than 20 
medium size drusen or retinal pigmentary abnormalities (Figure 1.6A). At this 
stage, blurred vision and abnormal dark adaptation may occur, but the visual loss 
is generally mild and the visual symptom is inconspicuous. Intermediate AMD 
(AREDS category 3) is characterized by at least one large drusen, numerous 
medium size drusen, or geographic atrophy (GA) that does not extend to the 
center of the macula (Figure 1.6B). Advanced AMD (AREDS category 4) include 
non-neovascular advanced dry AMD (geographic atrophy) and neovascular or 
wet AMD.  
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Figure 1.5. Normal Fundus. The area within the outer white circle (indicating 
a retinal diameter of about 6 mm) is the macula. The inner circle (diameter, 0.8 
mm) borders the fovea, which is the center of the macula, where the 
preponderance of cones over rods is highest for sharp vision. The retina is the 
inner lining at the back of the eyeball. The enlarged part shows the two outer 
layers that contain the purple light-sensitive rod and cone photoreceptor cells 
supported by Müller cells, all embedded in the inter-photoreceptor matrix, in 
close contact with the RPE. The RPE is surrounded by two extracellular 
matrixes, the inter-photoreceptor matrix and Bruch’s membrane. Between the 
RPE and the outer wall of the eye (sclera) are Bruch’s membrane, the 
choriocapillaris, and a larger vessel layer, the choroid. (Reproduced from de 
Jong et al., 2006). 
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Figure 1.6. Classification of AMD. Column A indicates early AMD in two 
maculas: the macula shown on the left side contains small drusen (arrow) and 
some large, indistinctly bordered drusen in the fovea; the macula shown on 
the right side contains more drusen and focal hyperpigmentation (arrow); 
column B shows intermediate AMD with crystalline and calcified drusen 
(arrows on the left); on the right side are large confluent drusen leading to a 
drusenoid detachment of the RPE, with hyperpigmentation (arrows); column C 
shows advanced dry AMD (geographic atrophy), with a central island in which 
photoreceptors are still functioning (arrow); column D shows wet AMD 
(choroidal neovascularization) with a subfoveal hemorrhage surrounded by 
detachment of the RPE (arrows) (Reproduced from de Jong et al., 2006). 
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          Advanced dry AMD or geographic atrophy (Figure 1.6C) is characterized 
by the regional loss of photoreceptor and RPE cells in the macula, gradually 
blurring central vision in the affected eye. Advanced neovascular AMD (wet 
AMD), also known as choroidal neovascularization (CNV) (Figure 1.6D) occurs 
when blood vessels in the choroid abnormally grow through Bruch’s membrane 
into the retina. These new blood vessels tend to be very fragile and often leak 
blood and fluid, and can rupture, rapidly causing irreversible damage to the 
macula. Although wet AMD represents less than 15% of AMD prevalence, it is 
responsible for more than 80% of the debilitating visual loss in AMD (Friedman et 
al., 2004). 
 
1.3.2 Risk Factors 
Demographic factors. The greatest risk factor for AMD is age. Age reflects the 
level of free radical oxidative damage accumulated in the body (Jager et al., 
2008). Although AMD may occur during middle age, studies show that people 
over age 60 are clearly at greater risk than younger age groups. The incidence, 
prevalence, and progression of all forms of AMD increases with advancing age 
(Smith et al., 2001; Klein et al., 2002; Mitchell et al., 2002a).  
          Epidemiological studies show significant variation in the prevalence of 
advanced AMD among different racial/ethnic groups. All forms of AMD are more 
prevalent in the white population than more darkly pigmented races (Pieramici et 
al., 1994; Friedman et al., 1999; Klein et al., 2003), which suggests that melanin 
may be protective in darkly pigmental races. The presence of melanin also 
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seems to protect against formation of RPE lipofuscin, a marker of cellular 
senescence and promoter of oxidative damage (Kayatz et al., 2001; Sundelin et 
al., 2001). 
 
Genetic factors. Genetic background influences susceptibility to AMD. Much 
evidence points to a familial component of AMD, including twin-concordance, 
linkage studies, and biomolecular investigations (Meyers et al., 1994).  Recently, 
common genetic polymorphisms in different complement genes have been 
reported to increase risk or confer protection for AMD. Genetic variants of the 
CFH (complement factor H), ARMS2 (age-related maculopathy susceptibility 2, 
also known as LOC387715), HTRA1 (high temperature requirement factor A1), 
C3 (complement 3) and CFHR5 (complement factor H related 5) genes have 
been shown to be associated with an increase risk for AMD in Caucassian 
populations (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; 
Klein et al., 2005; Rivera et al., 2005; Gold et al., 2006; Hageman et al., 2006; 
Yates et al., 2007). In particular, the CFH His402 variant, located in the short 
consensus repeat 7 (SCR7) of factor H, has consistently been shown to be 
associated with increased risk to AMD in numerous studies (Hageman et al., 
2005; Scholl et al., 2007).  
 
Smoking. Cigarette smoking is a significant risk factor for AMD. Smoking has 
been associated with an increased risk of developing AMD in most population 
based studies (Delcourt et al., 1998; Klein et al., 1998). Both prior and current 
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smokers are at increased risk for AMD (Hyman et al., 1983; Smith et al., 1996), 
and these individuals tend to develop AMD 5 to 10 years before non-smokers, 
respectively (Mitchell et al., 2002b). This may be due to smoking’s effect on 
antioxidant metabolism and choroidal blood flow. 
 
1.3.3 AMD Disease Mechanisms 
          Although genetic and environmental factors contribute to age-related 
macular degeneration (AMD), specific mechanisms of disease onset and 
progression remain unclear. Current pathophysiologic concepts suggest that 
AMD is a multi-factorial disease, that affects initially the RPE and the thin 
connective tissue layer (Bruch’s membrane) interposed between the RPE and 
choriocapillaris (Jager et al., 2008). Electron microscopy reveals accumulation of 
lipofuscin granules in the cytoplasm of RPE, and the deposition of randomly 
distributed amorphous or granular material (drusen) in Bruch’s membrane 
(Feeney et al., 1985). Histochemically, lipofuscin appears to contain mainly 
extracellular matrix-associated lipids and glycoproteins (Hageman et al., 1999). 
However, recent proteomic analyses of RPE lipofuscin show that the granules 
contain very little protein but do exhibit oxidative protein metabolism (Ng et al., 
2008). The apparent impairment of metabolic exchange between the 
choriocapillaris and the RPE leads to secondary degeneration of photo-receptor 
cells, which subsequently results in further deposition of abnormal metabolites on 
the Bruch’s membrane, and finally, induces the permanent loss of the visual 
functions in the affected macular area (Bird et al., 1992; Starita et al., 1997). 
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Biochemical studies suggest that increasing lipid deposits in Burch’s membrane 
exponentially correlate with age, with the macular area preferentially affected 
(Holz et al., 1994).  
 
1.3.4 Treatment 
          Choroidal neovascularization (CNV), the wet form of advanced AMD, is 
responsible for more than 80% of legal blindness caused by AMD. Wet AMD can 
be treated most effectively with ocular injections of anti-VEGF (vascular 
endothelial growth factor). Abnormally high levels of VEGF occur in eyes with wet 
AMD and promote the growth of new blood vessels. Treatment with anti-VEGF 
blocks the effects of VEGF. It can help slow down vision loss from AMD and in 
some cases improve sight (Gragoudas et al., 2004; Rosenfeld et al., 2006). 
However, there is still no effective treatment for dry AMD. 
          Laser surgery has been used to destroy fragile, leaky blood vessels, 
however, laser treatment may also destroy surrounding healthy tissue and vision. 
Only a small percentage of people with wet AMD can be treated with laser 
surgery. The risk of new blood vessels developing after laser treatment is high 
and vision loss often progresses despite repeated treatments (Jager et al., 2008). 
          Photodynamic therapy has also been used to treat wet AMD. A 
photosensitizing drug such as verteporfin is injected in the blood stream, then, is 
activated by a 689 nm laser focused on the macula. The activated drug destroys 
the new blood vessels and slows the rate of vision decline, but treatment results 
often are temporary (Jager et al., 2008). 
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1.4 Oxidative Stress 
          Molecular dioxygen, O2, is essential for cellular respiration in all aerobic 
organisms. Oxygen is used in mitochondria to help generate adenosine 
triphosphate (ATP) during oxidative phosphorylation. However, oxidative stress 
has been implicated in variety of disease processes, especially age-related 
disorder, including the cardiovascular disease (Damy et al., 2004; Dalle et al., 
2006), eye diseases like age-related macular degeneration (Beatty et al., 2000; 
Crabb et al., 2002; Gu et al., 2003; Zarbin et al., 2004; Ebrahem et al., 2006; 
Shen et al., 2007; Trieschmann et al., 2007; Hollyfield et al., 2008).  
 
1.4.1 Chemistry of Oxidative Stress 
          Oxidative stress is caused by an imbalance between the production of 
reactive oxygen and a biological system’s ability to readily detoxify the reactive 
intermediates or easily repair the resulting damage. The particularly destructive 
aspect of oxidative stress is the production of reactive oxygen species (ROS), 
which include free radicals (such as superoxide and hydroxyl ion), hydrogen 
peroxide, and singlet oxygen (Figure 1.7) (Winkler et al., 1999). These ROS are 
often the byproducts of oxygen metabolism. The main sources of intracellular 
ROS generation are the mitochondrial and microsomal electron transport chains 
and NAD(P)H oxidases. These ROS are highly reactive due to the presence of 
unpaired valance shell electrons. ROS form as a natural byproduct of the normal 
metabolism of oxygen and have important roles in cell signaling. However, during 
times of environmental stress, ROS levels can increase dramatically, which can 
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result in significant damage to cell structure. This oxidative damage initiated by 
ROS is a major contributor to the functional decline that is characteristic of aging. 
 
 
1.4.2 Oxidative Stress in the Retina 
          The retina is particularly susceptible to oxidative stress because of its high 
consumption of oxygen, its high proportion of polyunsaturated fatty acids (PUFA) 
(Beatty et al., 2000), and its exposure to visible light. The RPE also generates 
O2
H2OH2O2O2
●¯
H2O
1O2
OH●
e¯
e¯ + 2H+ e¯ + H+ e¯ + H+
Singlet oxygen
Superoxide anion Hydrogen peroxide Hydroxyl radical
Figure 1.7. Generation of Reactive Oxygen Radicals. Oxygen accepts an 
electron to form the superoxide anion, which in turn can accept another 
electron and react with protons to form hydrogen peroxide. The hydrogen 
peroxide is easily degraded to hydroxyl radical, which is very reactive and 
subsequently is neutralized by accepting a proton. Singlet oxygen is 
generated when a chromophore absorbs energy and transforms the energy 
to molecular oxygen (Reproduced from Winkler et al., 1999). 
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ROS from phagocytosis (Miceli et al., 1994) of the photoreceptor outer segments 
(POS) that contain high concentrations of radicals, photo-damaged proteins and 
oxidized lipids. Some of these oxidative-damaged proteins and lipids are not 
completely digested by RPE lysosomes and accumulate within RPE cells and 
become a major source of photosensitizer lipofuscin during RPE aging (Kennedy 
et al., 1995). 
          In healthy retina, the RPE can defend against oxidative stress by (1) 
absorbing and filtering light, (2) detoxifying ROS by enzymatic and non-
enzymatic antioxidants, and (3) self-repairing damaged macromolecules. Various 
pigments in RPE and photoreceptor cells are able to absorb light of different 
wavelengths (Landrum et al., 1999; Beatty et al., 2001). Blue light is most 
dangerous for RPE, since it triggers photo-oxidation of lipofuscin and other 
components to generate toxic substances (Rozanowska et al., 1995; Sparrow et 
al., 2000). High amounts of catalase (Miceli et al., 1994; Tate et al., 1995), 
superoxide dismutase (Oliver et al., 1992; Frank et al., 1999), and glutathione as 
well as carotenoids (Newsome et al., 1994; Beatty et al., 2000) help detoxify and 
remove ROS once they are generated in RPE cells. 
 
1.4.3 Oxidative Stress and AMD 
          Oxidative stress may play a major role in the etiology and pathogenesis of 
AMD. Vision loss in AMD results from photoreceptor and RPE damage in the 
central retina and the initial pathogenesis appears to involve degeneration of 
RPE cells (Green et al., 1985; Spraul et al., 1996; Zarbin et al., 1998).  Because 
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of the close interaction between RPE and photoreceptors in both nutritional and 
metabolic aspects (Marmorstein et al., 1998), progressive RPE dysfunction is 
thought to cause a secondary degeneration of rods and cones. The pathological 
changes leading to the loss and/or dysfunction of macular RPE cells is thought to 
involve oxidative stress and to be central to the etiology of this disease.  
          Lifelong chronic cumulative oxidative stress constitutes a significant risk 
factor for AMD because the retinal environment favors the generation of ROS 
(van der Hagen et al., 1993; Snodderly et al., 1995; Rose et al., 1998; Winkler et 
al., 1999). Evidence from a variety of studies suggests that RPE cells are 
susceptible to oxidative damage (Liang et al., 2003). Thus, it is of considerable 
interest to understand factors that modulate RPE cell function and viability in an 
oxidative stress environment. Elucidating the mechanism responsible for RPE 
oxidative injury could provide the basis for designing new strategies to treat or 
prevent AMD disease.  
          The relationship between oxidative stress and AMD is supported by 
epidemiologic evidence pointing toward multiple oxidative process-related factors. 
These factors include age, environmental inducers such as cigarette smoking 
(Chan et al., 1998; Schmidt et al., 2005), intense sunlight exposure 
(Cruickshanks et al., 1993), and antioxidant status, all of which can possibly 
enhance ROS generation and increase the risk for RPE degeneration. Previous 
studies reveal that heavy cigarette smokers have a 2.4 times higher risk of AMD 
(Seddon et al., 1996; Chan et al., 1998).  
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          Antioxidant carotenoids and vitamins have been hypothesized to play a 
protective role against oxidation.  Lutein and zeaxanthin exist in high 
concentrations in the macula and are entirely of dietary origin.  The antioxidant 
properties of the carotenoids include the ability to quench free radical reactions 
and therefore prevent lipid peroxidation and protect against photochemical 
reactions (Krinsky et al., 1982; Packer et al., 1993).  Vitamin C, the most effective 
aqueous phase antioxidant in serum (Frei et al., 1989), and vitamin E, the major 
chain-breaking antioxidant of cellular membranes (Packer et al., 1990) are two 
other antioxidants essential for protection against disease progression and 
degenerative disorders caused by oxidative stress.  The Eye Disease Case 
Control (EDCC) study reported that high dietary and serum levels of carotenoids 
and a high antioxidant index (a composite score based on serum carotenoids, 
selenium, vitamin C and E) was significantly associated with reduced risk of AMD 
progression (EDCC Study Group, 1993). Several other case control and 
population based studies have demonstrated inconsistent results.  However, the 
overall evidence suggests the existence of an important association between 
antioxidants and AMD, especially considering potentially modifiable risk factors 
like smoking.  
 
1.4.4 Carboxyethylpyrrole Biomarkers of AMD 
        Carboxyethylpyrrole (CEP) modifications are generated by covalent 
adduction of primary amino groups (e.g., protein ε-lysyl NH2) with 4-hydroxy-7-
oxohept-5-enoic acid, an oxidation fragment derived uniquely from DHA-
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containing phospholipids (Gu et al., 2003).  DHA is the most oxidizable of all fatty 
acids and although rare, its highest abundancy in human tissues is found in 
retinal photoreceptor outer segments (Fliesler et al., 1983).  The high oxygen 
tension in the retina coupled with light provides a permissive environment for the 
generation of oxidative post-translational modifications.  For example, rodents 
exposed to intense light accumulate elevated CEP adducts in the retina and 
elevated CEP adducts and autoantibodies in plasma (Gu et al., 2004; 
Renganathan et al., 2003).  Why ocular tissues in AMD patients are more 
susceptible to oxidative damage than normal eye tissue remains to be 
determined but oxidative markers formed from retina-rich components like DHA-
lipids offer a potential early warning system for predicting AMD susceptibility. 
        CEP protein adducts belong to a family of 2-(ω-caroxyalkyl)pyrrole adducts 
generated from the oxidation of polyunsaturated fatty acids (PUFAs) (Figure 1.8) 
(Gu et al., 2003).  Oxidative fragmentation of linoleic and arachidonic acid 
produces oxidation products that react with proteins to generate 2-(ω-
caroxyheptyl)pyrrole (CHP) and 2-(ω-caroxypropyl)pyrrole (CPP) adducts, 
respectively (Kaur et al., 1997).  The CHP and CPP adducts were detected in 
oxidized low density lipoprotein and human plasma (Kaur et al., 1997).  The 
phosphatidylcholine (PC) esters of these PUFA oxidation products are also 
biologically active products of oxidized low density lipoprotein oxidation (oxLDL).  
They are found in atherosclerotic plaques and oxLDL (Podrez et al., 2002; 
Subbanagounder et al., 2002; Sun et al., 2002).  The detection of CPP or CHP 
does not uniquely indicate the oxidative damage of linoleic or arachidonic acid 
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because these protein adducts can also arise from other common PUFAs.  In 
contrast, only docosahexaenoic acid (DHA) gives rise to 2-(ω-caroxyethyl)pyrrole 
(CEP) adducts, by oxidative cleavage to 4-hydroxy-7-oxohept-5-enoic acid and 
reaction of the latter with proteins. 
 
 
 
Figure 1.8. Generation of Carboxyethylpyrrole Adducts.  Oxidative 
fragmentation of polyunsaturated fatty acids generates a host of oxidation 
products, including the hydroxy-ω-oxoalkenoic acids HODA, HOOA and 
HOHA which give rise to a host of protein modifications, including the family of 
carboxyalkylpyrrole protein adducts CHP, CPP and CEP.  HODA, 9-hydroxy-
12-oxodec-10-enoic acid; HOOA, 5-hydroxy-8-oxooct-6-enoic acid; HOHA, 4-
hydroxy-7-oxohept-5-enoic acid; CHP, 2-(ω-carboxyheptyl)pyrrole; CPP, 2-(ω-
carboxypropyl)pyrrole; CEP, 2-(ω-carboxyethyl)pyrrole (Reproduced from Gu 
et al., 2003). 
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1.5 Advanced Glycation End-Products 
1.5.1 Glycated Modification of Proteins 
          Extracellular and cellular proteins can be modified by the Maillard reaction 
(Maillard et al., 1912; Glomb et al., 2001), which involves glycation, or non-
enzymatic glycosylation. The aldehyde groups of glucose and other reducing 
sugars can react reversibly with primary amino groups of proteins to form Schiff 
bases and Amadori adducts (Figure 1.9). Overtime, the initial glycation products 
may undergo subsequent intramolecular rearrangements and oxidation reactions 
(glycoxidation) and ultimately transform into stable, irreversibly bound advanced 
glycation end-products (AGEs) (Ahmed et al., 1997) (Figure 1.10). The amino 
groups of the side chains of arginine and lysine are the primary targets for this 
type of posttranslational oxidative modification. AGEs appear to play an 
important role in age-related pathologies. 
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Figure 1.9. Non-Enzymatic Glycation, the Maillard Reaction. The primary 
amine group (nucleophilic) of an amino acid reacts with the reactive carbonyl 
group of a reducing sugar to produce N-substituted glycosylamine (Schiff 
base). The unstable glycosylamine undergoes Amadori rearrangement, 
transforming into more stable aldoamines (Amadori products). Following a 
chain of not well-understood chemical rearrangements, the Amadori products 
are irreversibly bound to the target molecules and finally form the advanced 
glycation end-products (AGEs) (Reproduced from Niwa et al., 2006). 
 
Figure 1.10. Pathways for the Formation of AGEs (Reproduced from 
Thornalley et al., 2003). 
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1.5.2 Molecular Structures and Formation of Several AGEs 
          Recent investigations have revealed that AGEs may play a role in aging 
changes (Sell et al., 1990; Brownlee et al., 1995) and neovascularization 
(Yamagishi et al., 1997; Lu et al., 1998). They accumulate especially, but not 
exclusively, on long-lived structural proteins, such as collagens and lens 
crystallins, and are recognized as important instigators of age-related pathology 
by altering macromolecular structure and function (Monnier et al., 1992). 
Although these reactions occur during our entire life span, there is evidence that 
they are enhanced in pathogenic aging, leading to increased tissue levels of AGE 
adducts, such as Nε-(carboxymethyl)lysine (CML) (Shaw et al., 2002), 
pentosidine, and argpyrimidine (Figure 1.11A) (Thornalley et al., 1999; Wilker et 
al., 2001; Thorpe et al., 2003). Formation of AGEs is accelerated by oxidative 
stress (Singh et al., 2001). 
          Nε-(carboxylmethyl)lysine (CML) is a stable, nonenzymatic chemical 
modifications of protein lysine residues formed by oxidative breakdown of 
Amadori products (Fu et al., 1996) and during metal-catalyzed auto-oxidation of 
polyunsaturated fatty acids (PUFAs) in the presence of protein (Miyata et al., 
1998; Jump et al., 2002). This major modification by the Maillard reaction 
accumulates in several human tissues during aging and various diseases 
including AMD (Ishibashi et al., 1998) (Figure 1.11B). Previous studies have 
reported the concentration of CML in control plasma as measured by ELISA to 
be 0.97 nmol/ml(Sebeková et al., 2001), 1.81 nmol/ml (Heidland et al., 2004), 
2.09 nmol/ml (Krajcovicová et al., 2002). 
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          Pentosidine is an AGEs that crosslinks arginine and lysine residues in 
proteins with carbonyl derivatives (Figure 1.11B). The plasma concentration of 
pentosidine in normal controls has been reported from chromatographic analyses 
to be 0.90 pmol/mg (Odetti et al., 2005), 0.94 pmol/mg (Odetti et al., 1992) and 
1.27 pmol/mg (Słowik et al., 2004). 
          Argpyrimidine is a major arginine modification by methylglyoxal (Oya et al., 
1999). Methylglyoxal is produced from several metabolic pathways and has been 
detected in serum as well as tissues (Haik et al., 1994; Chaplen et al., 1998). 
Methylglyoxal is produced during the Maillard reaction with sugars such as 
glucose (Thornalley et al., 1999), and reacts rapidly with proteins to produce 
argpyrimidine (Phillips et al., 1993) (Figure 1.11B). Variable estimates of the 
argpyrimidine concentration in normal control plasma proteins have been 
reported, including 1 fmol/mg by ELISA (Raj et al., 2004), 4.4 pmol/mg by amino 
acid analysis (Wilker et al., 2001) and 13.9 pmol/mg by LC-mass spectrometry 
(Thornalley et al., 2003). 
          The fluorescence properties of pentosidine and argpyrimidine are similar 
with an excitation wavelength (λex) of 335 nm and an emission wavelength (λem) 
of 385 nm (Sell et al., 1989). 
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Figure 1.11. (A) Molecular Structures of AGEs; (B) Multiple Pathways 
Leading to Formation of CML, Pentosidine and Argpyrimidine. 
(Reproduced from Wilker et al., 2001; Shaw et al., 2002; Thornalley et al., 
2003).  
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1.5.3 Advanced Glycation End-Products and Disease 
          AGEs are a complex and heterogeneous group of compounds that have 
been implicated in diabetes related complications. At present it is not known if 
they are the cause or the consequence of the complications. The presence of 
advanced glycation end-products (AGE) is closely related to hyperglycaemia and 
may be involved in diabetes related complications such as retinopathy, 
neuropathy and nephropathy (Vlassara et al., 1996; Ulrich et al., 1997). Apart 
from diabetic microvescular disease, AGEs have also been implicated in a wide 
range of pathologies such as connective tissue diseases like rheumatoid arthritis 
and neurological conditions such as Alzheimer’s disease and end-stage renal 
disease (ESRD) (Bucala et al., 1992; Lee et al., 1992). Whether they are the 
cause of such pathologies or merely a by-product is not known. Despite their 
complexity and widespread distribution, the currently known AGEs represent the 
same chemical outcome, namely, the formation of covalent protein modifications 
(Bucala et al., 1997). 
          CML has been suggested to represent a general marker of oxidative stress 
and long term damage to proteins in aging, atherosclerosis, and diabetes (Reddy 
et al., 1995). Apparently glycation reactions initiate a complex series of oxidative, 
cleavage, and rearrangement reactions which lead to the accumulation of AGEs 
in diabetes and aging (Monnier et al., 1986; Brownlee et al., 1988; Makita et al., 
1992). Pentosidine has also been reported to increase in diabetes (McCance et 
al., 1993). Plasma pentosidine has been associated with hypertension, ischemic 
heart disease, and aortic calcification in diabetes (Kitauchi et al., 2004). The role 
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of different types of AGE in the pathogenesis of diabetic complications is still 
unclear. For example, serum levels of CML increase in diabetic patients with 
retinopathy but not with nephropathy whereas the levels of pentosidine increase 
in both groups (Miura et al., 2003).  
          Furosine (ε-N-furoylmethyl-L-lysine), a marker of early protein glycation, is 
formed during acid hydrolysis of the protein-bound Amadori product fructose-
lysine (Figure 1.12). This amino acid has been used to measure the early stages 
of Maillard reaction in biological samples. The yield of furosine is described to be 
constant under controlled conditions. Published yields range from 20% to 32% 
after hydrolysis in 6 M hydrochloric acid and from 29% to 46% after hydrolysis in 
7.8 M hydrochloric acid (Krause et al., 2003). Literature values for the plasma 
concentration of furosine in normal control from chromatographic analyses 
include 0.87, 0.91 and 1.01 nmol/mg plasma protein (Friedlander et al., 1996; 
Floridi et al., 1998; Riviere et al., 1998). The quantification of furosine can be 
used to predict the progression of diabetic complications (Monnier et al., 2005). 
Furosine was used to monitor possibly unknown diabetics in our study group. 
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1.5.4 AGEs in Age-related Macular Degeneration 
          Bruch’s membrane and the overlying RPE form a dynamic filtration barrier 
between the dense vascular network of the choriocapillaris and the retina. 
Bruch’s membrane displays structural and physiological changes with age, 
including reconfiguration of chemical composition and an increase in overall 
thickness (Okubo et al., 1999; Zarbin et al., 2004). AGEs accumulate during 
aging and have been observed in postmortem eyes within the RPE, Bruch’s 
membrane, and subcellular deposits (drusen) (Figure 1.13). Qualitatively, AGEs 
are increased in RPE, drusen, and Bruch’s membrane from aging eyes and in 
patients with AMD (Ishibashi et al., 1998; Handa et al., 1999; Glenn et al., 2007), 
and it has been shown that these adducts also occur in basal lamina deposits 
from human macula (Yamada et al., 2006). AGE formation with extracellular 
Figure 1.12. Chemical Pathways Leading to The Formation of Glycation 
(furosine) and Glycoxidation Product (the lipoxidation/glycoxidation product 
CML and pentosidine) (Reproduced from Frank et al., 2000). 
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matrices has been proposed to contribute to diminished barrier and filtration 
properties in Bruch’s membrane. Glycoxidation and lipoxidation reactions 
induced by oxidative stress have been linked to drusen formation and are 
proposed to contribute to the progression of AMD (Crabb et al., 2002). The 
extracellular deposits around Bruch’s membrane instigate chronic local 
inflammation, which contributes to the development of AMD (Sarks et al., 1999; 
Hageman et al., 2001).  
          The formation of CML has been shown to occur at sites of oxidative stress 
with hydroxyl radical formation (Nagai et al., 1997). CML has been detected in 
soft, macular drusen (Crabb et al., 2002) and in basal laminar and basal linear 
deposits (Figure 1.14) (Ishibashi et al., 1998). It has been suggested that oxidant 
stress may contribute to damage to Bruch’s membrane, facilitating choroidal 
neovascularization (CNV) (Ryan et al., 1994). The appearance of CML and CEP 
in drusen supports the hypothesis that oxidative protein modifications have a role 
in drusen formation and the pathogenesis of AMD.  
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Figure 1.13. AGE-Linked Autofluorescence in Human Bruch’s Membrane 
and RPE. A spectral imaging system was used to determine the presence of 
AGE-linked autofluorescence in human specimens. Sections were assessed 
by confocal microscopy, using a λ scan approach to identifying areas of 
autofluorescence within each set wavelength. Each different band was then 
pseudocolored for ease of identification, as shown in a representative sample 
from an 88-year-old man with some evidence of drusen. (A) Cell nuclei stained 
with DAPI (blue; arrows). (B) Localization of fluorescent AGEs within the RPE 
layer and Bruch’s membrane with excitation emission spectra in a 400- to 460-
nm range (red; left arrowhead: AGEs at the level of Bruch’s membrane; right 
arrowhead: AGEs in the RPE). The additional staining throughout the section 
is indicative of additional AGE accumulation in the collagenous choroids. (C) 
Autofluorescence (yellow) of lipofuscin (*) was also observed at a 
characteristic wavelength within the RPE cytoplasm. (D) Composite image of 
(A - C). Original magnification, x 600. (Reproduced from Glenn et al., 2009).  
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          The localization of pentosidine in human RPE-Bruch's membrane-choroid 
complexes has been reported from immunohistochemical experiments. In an 82-
year-old nondiabetic eye with no known history of AMD, Bruch's membrane, the 
extracellular matrix of the choroid, and choroidal vasculature showed 
immunohistochemical evidence of pentosidine (Figure 1.15A). In the 82-year-old 
nondiabetic eye, basal laminar deposits (BLDs) and drusen showed evidence of 
Figure 1.14. Immunohistochemistry for Nε-(carboxymethyl)lysine (CML).   
A: Soft, macular drusen in the eye of an 81-year-old woman (control). CML 
immunoreactivity is observed in Bruch’s membrane, and accentuated in the 
soft, macular drusen (arrow), and basal laminar and basal linear deposits 
(arrowheads). Note the absence of CML immunoreactivity in the RPE layer 
(original magnification 3100). B: A fibrous cellular choroidal neovascular 
membrane surgically excised from the eye of a 70-year-old man with age-
related macular degeneration. Partially intact RPE cells show CML 
accumulation (arrows) (original magnification 3100) (Reproduced from 
Ishibashi et al., 1998). 
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pentosidine. These structures showed prominent staining with the anti-
pentosidine antibody (Figure 1.15A, B) compared with the control sections 
(Figure 1.15C, D) (Handa et al., 1999). 
 
 
Figure 1.15. Immunohistochemical Localization of Pentosidine in Human 
Bruch's Membrane and Drusen. (A) In an 82-year-old nondiabetic eye 
without known AMD, Bruch's membrane including BLD and choroidal 
extracellular matrix and vasculature showed positive immunoreactivity. (B) A 
high-power image of a drusen (DRU) shows staining for pentosidine. (C) 
Minimal reaction was observed with addition of nonimmune rabbit IgG or (D) 
the anti-pentosidine antibody preincubated with excess pentosidine-modified 
BSA in the 82-year-old nondiabetic eye (Reproduced from Handa et al., 1999). 
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1.6 Long Term Goals and Specific Aims 
          The long term goal of this research is to develop methods to predict AMD 
susceptibility early, prior to clinical signs of the disease, essentially as serum 
cholesterol measurements are used today for risk management of cardiovascular 
disease. The specific aims of the thesis research are: (1) to quantify CML, 
pentosidine and argpyrimidine in AMD and control plasma as potential AMD 
biomarkers; and (2) to compare the discrimination accuracy of CML and 
pentosidine biomarkers for AMD with that of CEP biomarkers for AMD. 
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CHAPTER II 
EXPERIMENTAL METHODS 
 
 
 
2.1  Materials 
5% phenylisothiocyanate in n-heptane Applied Biosystems (Warrington, UK) 
AccQ•Tag™ Ultra borate buffer Waters (Milford, MA) 
AccQ•Tag™ Ultra Eluent A  Waters (Milford, MA) 
AccQ•Tag™ Ultra Eluent B Waters (Milford, MA) 
AccQ•Tag™ Ultra Reagent Waters (Milford, MA) 
AccQ•Tag™ Ultra reagent powder Waters (Milford, MA) 
Acetone, HPLC grade Fisher Scientific (Pittsburg, PA)  
Acetonitrile, HPLC Grade Fisher Scientific (Pittsburg, PA)  
Amino Acid Standard H Pierce (Rockford, IL) 
Amino Acid Standard H Thermo Scientific (Rockford, IL) 
Ammonium Acetate, HPLC Grade  J.T. Baker (Phillipsburg, NJ)  
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Butylated Hydroxytoluene (BHT) Sigma Chemical Co. (St. Louis, MO) 
Glacial Acetic Acid (AA) Fisher Scientific (Pittsburg, PA) 
Hydrochloride, Ultrapure Reagent J.T. Baker (Phillipsburg, NJ)  
Methanol, HPLC Grade  Fisher Scientific (Pittsburg, PA)  
N, N-diisopropylethylamine (DIEA) Applied Biosystems (Warrington, UK) 
Nε-(carboxymethyl)lysine (CML) NeoMPS, Inc. (San Diego, CA) 
Pentosidine IMARS (Cleveland, OH) 
Potassium EDTA solution  Applied Biosystems (Warrington, UK) 
Protease Inhibitor Cocktail Sigma Chemical Co. (St. Louis, MO) 
Sodium Acetate (NaAc)  Fisher Scientific (Pittsburg, PA) 
Sodium acetate buffer (3 M) pH = 3.8  Perkin Elimer (Warrington, UK)  
s-β(4-Pyridylethyl)-L-Cysteine (PEC) Sigma Chemical Co. (St. Louis, MO) 
Tetrahydrofuran (THF)  Sigma Chemical Co. (St. Louis, MO) 
Trifluoroacetic acid (TFA) Pierce (Rockford, IL) 
Water, HPLC Grade Honeywell Burdick&Jackson™ 
(Muskegon, MI)  
ε-N-(Furoyl-methyl)-L-lysine·2HCl 
(Furosine Dihydrochloride) 
NeoMPS, Inc. (San Diego, CA) 
 
2.2  Case-Control Study Design 
          Clinically documented control and AMD blood donors were recruited 
prospectively between 2005 and 2008 from the Cole Eye Institute, Cleveland 
Clinic Foundation with the approval of each Institutional Review Board and 
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according to Declaration of Helsinki principles. All patients received a 
comprehensive eye examination by a clinician and provided written informed 
consent. All human identifiers were removed from blood specimens and were 
encoded to protect donor confidentiality. AMD disease progression was 
categorized based on fundus examination and patients were included in the 
study from AREDS (The Age-Related Eye Disease Study Group) AMD 
categories 2, 3, 4. Briefly, AMD category 2 patients exhibited early-stage disease 
with multiple small drusen, single or nonextensive intermediate drusen (63-124 
µm), RPE pigmentary abnormalities, or any combination of these, in one or both 
eyes and visual acuity of 20/30 or better in both eyes. AMD category 3 patients 
exhibited mid-stage disease with at lease one eye with visual acuity 20/30 or 
better and one large drusen (125 µm), extensive intermediate drusen or 
geographic atrophy that did not involve the macula or any combination of these. 
Category 3 patients lacked advanced AMD in either eye. AMD category 4 
patients exhibited advanced AMD with substantial choroidal neovascularization 
(CNV) or geographic atrophy (GA) involving the macula in one or both eyes. 
Control donors lacked macular drusen and exhibited no clinical evidence of any 
retinal disorder. Plasma were prepared from blood specimens and stored frozen 
until analysis as described below. 
 
2.3  Human Plasma Preparation 
          Nonfasting blood specimens were collected in 4 ml BD Vacutainer® spray-
coated K2EDTA tubes and plasma was prepared within 6 hours and aliquotted to 
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vials containing butylated hydroxytoluene (BHT; 1 mg/ml plasma) and a protease 
inhibitor cocktail (10 µl/ml plasma) (Gu et al., 2003). The final concentrations of 
these additives in plasma were: BHT, 22 µg/ml; AEBSF (serine protease 
inhibitor), 1mM; aprotinin (serine protease inhibitor), 0.8 µM; leupeptin (serine 
and cysteine protease inhibitor), 20 µM; bestatin (aminopeptidase inhibitor), 40 
µM; pepstatin A (acid protease inhibitor), 15 µM; and E-64 (cysteine protease 
inhibitor), 14 µM. The plasma was flushed with argon, quench-frozen in liquid 
nitrogen immediately and stored at - 80°C. Storage time ranged from 4 - 34 
months and averaged 13 month. All samples were frozen and thawed only once. 
 
 
2.4  Plasma Protein Quantification by Amino Acid Analysis 
          Phenylthiocarbamyl (PTC) and AccQ•Tag™ amino acid analysis were 
used to quantify plasma proteins. The following steps of sample preparation and 
analysis were performed: (1) precipitation of plasma proteins; (2) HCl hydrolysis 
of the plasma proteins; (3) PTC or AccQ•Tag™ derivatization of the amino acids; 
(4) chromatographic analysis, and (5) quantitative data interpretation. 
 
2.4.1 Precipitation of Plasma Protein 
          To obtain the most accurate amino acid analysis data, protein samples 
should be homogeneous, free of salts and detergents. The solubility of proteins is 
greatly influenced by the dielectric constant of the solution. In general, solvent 
molecules with large dielectric constants, such as water, can stabilize the 
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interaction between themselves and protein molecules and favor the dissolution 
of protein. On the other hand, organic solvents with small dielectric constant, 
such as acetone, discourage the dispersion of protein molecules in the media. 
Thus, the solubility of proteins can be lowered and precipitation can be induced 
by lowering the effective dielectric constant of the media. This is commonly 
achieved by adding a water soluble solvent such as acetone to an aqueous 
solution of protein. 
          Acetone precipitation: Plasma samples (200 µl, ~ 11 mg) were transferred 
to 6 × 50 mm hydrolysis tubes and protein was precipitated by adding 2 volumes 
(400 µl) of cold acetone. The tube was sealed with Parafilm, the solution was 
mixed and incubated 10-20 min at 4°C, then centrifuged briefly (10,000 rpm, 
table top centrifuge) to pellet protein and the supernatant was carefully removed 
and discarded. The pellet was washed once with 400 µl of 67% acetone and 
vacuum dried (Crabb et al., 1997).  
 
2.4.2 HCl Hydrolysis 
          Key to the success of protein amino acid analysis is the hydrolysis of the 
polypeptides into free amino acids. Complete hydrolysis was originally performed 
by heating the protein sample in constant-boiling HCl. However, vapor-phase 
hydrolysis methods are now often preferred because they are more rapid than 
the liquid-phase methods, and they reduce the possibility of introducing 
background contaminants with HCl.  
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          Hydrolysis: A diamond pencil was used to etch identity numbers on the 
tubes. After drying the sample, 60 µl of 6 M HCl was added to each hydrolysis 
tube to cover the pellet and the tubes were placed into a 40 ml screw-cap vial 
containing 300 µl of 6 M HCl and a few crystals of phenol (~ 1-2 mg). The 40 ml 
vial was capped with a modified Mininert slide valve and connected to vacuum 
and argon flush systems via a three-way stopcock. Argon gas and vacuum were 
alternatively donated into the vial three times to effectively remove the air from 
the vial (Crabb et al., 1997). The vial was finally sealed under vacuum and was 
heated at 110°C for 16 hours to vapor phase hydrolyze the protein pellets. 
Following hydrolysis, the Mininert valve was opened carefully in a fume hood to 
release the HCl vapor and the hydrolysis tubes were vacuum dried, flushed with 
Argon and stored at - 20°C until analysis. Bovine serum albumin (BSA) (~ 220 µg) 
obtained from National Bureau of Standard (NBS) was also hydrolyzed as a 
quantitative standard and stored in the same way as the plasma samples. For 
PTC amino acid analysis, hydrolysates were resuspended in H2O (600 µl). After 
PTC amino acid analysis, the hydrolysates were vacuumed dried and 
resuspended in 50 µl H2O for all subsequent analyses. 
 
2.4.3 Derivatization of the Amino Acids  
2.4.3.1 PTC Amino Acid Analysis 
          Phenylthiocarbamyl amino acid analysis (PTC-AAA) utilizes precolumn-
derivatization with phenylisothiocyanate (PITC) followed by reversed-phase high 
performance liquid chromatography (RP-HPLC) (Crabb et al., 1997). 
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          Chemicals: The derivatization reagents, 5% PITC in n-heptane and N, N-
diisopropylethylamine (DIEA), were purchased from Applied Biosystems. 
Methanol was HPLC grade from Fisher Scientific. Standard amino acids 
(Standard H) for the calibration were obtained from Pierce. Sodium acetate buffer 
(3 M, pH = 3.8 and pH = 5.5) separation grade, were purchased from Perkin 
Elimer. The later buffer was also made by ourselves. Potassium EDTA solution 
(50 mg/ml) was obtained from Applied Biosystems. Water (Burdick&Jackson™) 
and acetonitrile (Fisher Scientific) were both HPLC grade. 
          PTC Derivatization: After hydrolysis, the hydrolyzed amino acids were 
converted into phenylthiocarbamyl (PTC) derivatives for UV visibility (Figure 2.1). 
The derivatization was accomplished by coupling the amino group of the amino 
acid with PITC in basic solutions. Plasma hydrolysate (5 µl, ~ 82 µg protein) was 
transferred to a clean Eppendorf tube and dried. The sample was neutralized by 
adding 100 µl of the base DIEA in methanol (1:2 v/v) and re-dried. The PITC 
coupling reagent (PITC:DIEA:methanol, 2:2:7) was added (75 µl per tube) and 
the mixture was incubated at 25°C for 20 minutes. After incubation, the samples 
were dried and analyzed immediately, or stored at -20°C under argon until 
analysis. NBS-BSA standard samples were derivatized in the same way. 
Standard amino acids (Pierce standard H) were diluted to 60 pmol/µl in water 
and stored at -20°C until use. Standards H (20 µl, 1.2 nmol) was dried and re-
dried from DIEA (20 µl) as above. The PITC Coupling Reagent (15 µl) was added 
and incubated at 25°C for 20 minutes, then the derivatized standard amino acids 
were dried down and analyzed or stored as above. 
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          HPLC analysis: The analysis of PTC-derivatized amino acids was 
performed on an Agilent 1100 HPLC system coupled in-line with a UV Detector 
(GILSON, Model 116). Derivatized hydrolysates were dissolved in transfer buffer 
(240 µl) (29 mM sodium acetate, pH 5.2, 0.1 mg/ml K3EDTA) and 8 µl (~ 2.7 µg) 
was injected onto a HAISIL PTC C18 reversed-phase column (220 × 2.1 mm, 
Applied Biosystem) using gradient elution (Table 2.1). Column temperature was 
controlled at 30°C. The PTC-derivatized amino acids were monitored with the UV 
detector at λ = 254 nm. Analyses were performed in duplicate. Standard H amino 
acids (480 pmol) were analyzed using the same chromatographic method and 
repeated six times to obtain average results for calibrating the system. 
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Figure 2.1. PTC Derivatization. Phenylthiocarbomyl (PTC) amino acids were 
formed by derivatizing amino acids with phenylisothiocyannate (PITC) under 
basic condition (A). Side products were also produced by the reaction of PITC 
with other amino groups (B) (Reproduced from Crabb et al., 1997).  
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2.4.3.2 AccQ•Tag™ Amino Acid Analysis 
          The AccQ•Tag™ Ultra Reagent (6-aminoquinolyl-N-hydroxysuccinimidyl 
carbamate, or AQC) is an N-hydroxysuccinimide-activated heterocyclic 
carbamate, an amine derivatizing compound. It converts both primary and 
secondary amino acids to stable derivatives, as illustrated in Figure 2.2 (Cohen 
et al., 1993; Ward et al., 1996). 
          Chemicals: The AccQ•Tag™ Ultra derivatization kit, including AccQ•Tag™ 
Ultra borate buffer, AccQ•Tag™ Ultra reagent powder, AccQ•Tag™ Ultra reagent 
diluent were purchased from Waters, as were the AccQ•Tag™ Ultra Eluent A 
concentrate and AccQ•Tag™ Ultra Eluent B. Amino acid hydrolysate standards 
(Thermo Scientific) were diluted to 500 pmol/µl in water and stored at -20°C until 
use. Different dilution ratios were used when preparing the calibration curve. 
Table 2.1. Gradient Profile for PTC Amino Acid Analysis 
Analysis Time (min) 0 6 8 17.5 19.5 
Sovent A (%) 95 85 74 64 0 
Sovent B (%) 5 15 26 36 100 
Solvent A: 3% (v/v) acetonitrile, 50 mM sodium acetate, pH 5.4 
Solvent B: 70% (v/v) acetonitrile, 32 mM sodium acetate, pH 6.1 
Flow Rate: 300 µl/min 
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          AccQ•Tag™ derivatization: The Waters AccQ•Tag™ derivatization reagent 
was prepared by adding the appropriate AccQ•Tag™ Ultra reagent diluent (1ml) 
to the AccQ•Tag™ power reagent provided in the kit, then the solution was 
heated for 10 minutes at 55°C. Plasma hydrolysates (~ 3.53 µg protein in 10 µl 
water) were transferred to reaction vials (Waters) and the AccQ•Tag™ Ultra 
borate buffer (70 µl) was added to adjust the pH between 8 and 10. Then 
reconstituted AccQ•Tag™ Reagent (20 µl) was added, mixed and heated for 10 
Figure 2.2. AccQ•Tag™ Derivatization. The AccQ•Tag™ Ultra Reagent 
reacts rapidly with primary and secondary amino acids to yield highly stable 
urea. The structure of the derivatizing group is the same for all amino acids, 
adding the UV absorbance character. Excess reagent hydrolyzes to yield 6-
aminoquinoline (AMQ), a non-interfering by-product (Reproduced from Cohen 
et al., 1993). 
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minutes at 55°C. The standard amino acid prepared was derivatized in a similar 
manner. AccQ•Tag™ derivatized samples were analyzed using the Waters 
ACQUITY Ultra Performance LC® (UPLC®) system using 1 µl  injections for 
optimum resolution and sensitivity and the AccQ•Tag™ Ultra Column (100 × 2.1 
mm) (Waters) with gradient elution (Table 2.2). AccQ•Tag amino acids were 
detected with the ACQUITY UPLC® Tunable UV (TUV) Detector at 260 nm. 
 
          Furosine (ε-N-furoylmethyl-L-lysine) (NeoMPS, Inc. San Diego, CA), a 
form of glycated lysine, is detectable following acid hydrolysis of the Amadori 
compound. In this thesis, furosine was quantified by AccQ•Tag™ amino acid 
analysis using the method described above. The plasma hydrolysates (~ 15 µg 
protein) were dried in reaction vials, the AccQ•Tag™ Ultra borate buffer (35 µl) 
and the reconstituted AccQ•Tag™ Reagent (20 µl) was added, mixed and heated 
for 10 minutes at 55°C, 10 µl out of the total 55 µl was injected on the column. 
Table 2.2. Gradient Profile for AccQ•Tag™ Amino Acid Analysis 
Analysis Time (min) 0 0.54 5.74 7.74 8.04 8.05 
Sovent A (%) 99.9 99.9 90.9 78.8 40.4 10.0 
Sovent B (%) 0.1 0.1 9.1 21.2 59.6 90.0 
Solvent A: Dilution of concentrated AccQ•Tag™ Ultra Eluent A (140 mM 
sodium acetate containing 17 mM triethylamine, pH 5) with H2O 
in the ratio  
                 of 1 : 19 
Solvent B: AccQ•Tag™ Ultra Eluent B (60% acetonitrile, 40% water) 
Flow rate: 700 µl/min 
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The gradient was modified to optimize the resolution of furosine peak 3 (Table 
2.3). 
 
2.4.3.3 Data Analysis 
          Quantification of plasma protein: For unknown plasma samples, the amino 
acid residue weights were multiplied by the pmol analyzed for each amino acid 
and then summed to obtain the amount of protein analyzed. The plasma protein 
concentration was determined by multiplying the amount analyzed by the ratio of 
amount applied to the analyzer. 
          Quantification of BSA: For homogeneous BSA samples we used the pmol 
analyzed for each amino acid and the known protein composition to determine 
pmol protein based on each amino acid. The amount analyzed was estimated by 
averaging each of the residue estimates of pmol protein, then values were 
discarded that were greater than 15% from the mean. The final pmol protein 
Table 2.3. Gradient Profile for Quantification of Furosine using 
AccQ•Tag™ Amino Acid Analysis 
Analysis Time (min) 0 0.54 4.24 5.00 7.80 7.90 8.50 8.51
Sovent A (%) 99.9 99.9 94.4 89.9 75.0 32.0 32.0 10.0
Sovent B (%) 0.1 0.1 5.6 10.1 25.0 68.0 68.0 90.0
Solvent A: Dilution of concentrated AccQ•Tag™ Ultra Eluent A (140 mM 
sodium acetate containing 17 mM triethylamine, pH 5) with H2O in 
the ratio  
                 of 1 : 19 
Solvent B: AccQ•Tag™ Ultra Eluent B (60% acetonitrile, 40% water) 
Flow rate: 700 µl/min 
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analyzed was determined by averaging the remaining residue values. The BSA 
sample concentration was determined by multiplying the pmol protein by the ratio 
of the sample applied to the analyzer. BSA was converted to micrograms by 
multiplying pmol protein by the molecular weight (MW = 66,328). 
          Quantification of furosine: Large amounts of plasma hydrolysates were 
analyzed in order to quantify furosine, which is usually present in plasma in 
relative low amounts. A linear response of AccQ•Tag™-derivatized amino acids, 
including furosine, was obtained in the range of 0.5 pmol to 2000 pmol. Amounts 
out of this range were discarded. Ile and Leu were discarded because they are 
co-elute with mono-derivatized furosine. Ser and Thr are partially destroyed by 
HCl hydrolysis and Met is subject to oxidation, so these residues were not 
included in the final calculation. The remaining residues were selected based on 
values within 15% of the mean. Furosine concentration relative to protein was 
calculated by dividing the amount of furosine (pmol) by the corresponding 
amount of plasma protein (µg). 
 
2.5  Quantification of Advanced Glycation End-Products (AGEs) 
          Carboxymethyllysine (CML), pentosidine and argpyrimidine were analyzed 
in plasma protein HCl hydrolysates following a two-step HPLC separation using 
mass spectrometry and fluorimetry.  
          Chemicals: CML was purchased from NeoMPS, Inc. (San Diego, CA). 
Pentosidine was purchased from International Maillard Reaction Society (IMARS) 
(Case Western Reserve University, Cleveland, OH). Argpyrimidine was obtained 
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from Dr. Ram Nagaraj (Case Western Reserve University). s-β(4-Pyridylethyl)-L-
Cysteine (PEC) (Sigma) was used as internal standard to correct for losses 
during chromatography. Trifluoroacetic acid (TFA) (Pierce), acetic acid (AA) 
(Trace metal grade, Fisher Scientific), tetrahydrofuran (THF) (Sigma), sodium 
acetate (NaAc) (Anhydrous, Fisher Scientific), ammonium acetate (HPLC grade, 
J.T. Baker), waters (HPLC grade, Burdick&Jackson™), and acetonitrile (HPLC 
grade, Fisher Scientific) were used to prepare mobile phases. 
          HPLC System I: A Hypercarb™ porous graphitic carbon column (5 µm 
particles, 50 × 10 mm) (Thermo Scientific) was employed for the initial 
chromatography for AGEs quantification. The Hypercarb™ column is particularly 
useful for the separation of highly polar compounds which are difficult to retain on 
C18 reverse phases. Plasma hydrolysate (40 µl, ~ 8 mg protein) was analyzed 
using gradient separation (Table 2.4), a flow rate of 1 ml/min, a column 
temperature of 30°C, and an Agilent 1100 HPLC system. The HPLC eluent was 
directed first to a Waters™ 474 Scanning Fluorescence Detector (λexcitation / 
λemission = 335/385 nm) to quantify argpyrimidine and pentosidine which are 
naturally fluorescent. Following fluorescence detection, the eluent was split with 
80% directed to a fraction collector and 20% directed to a SCIEX API 3000 triple 
quadrupole electrospray mass spectrometer (Applied Biosystem). Glycation 
markers were detected in the positive ion mode using tandem mass spectrometry 
and multiple reaction monitoring (MRM), in which both parent ions and fragment 
ions were monitored in Q1 and Q3, respectively (Figure 2.3). Different 
fragmentation voltages were tested to optimize the MRM transitions for 
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quantitation. The most intense fragment ion and the precursor ion were used to 
monitor the AGEs. Tuning was also done with collision energy in order to obtain 
the most favorable signal to noise ratio. Ionization source temperature was 
425°C, and the programmed parameters and collision energies were optimized to 
± 0.1 Da and ± 1 volts (Table 2.5).  
 
Table 2.4. Gradient Profile for Separation of AGEs on the Hypercarb™ 
Column in HPLC System I 
Analysis Time (min) 0 3.8 4 8 12 13 16 
Sovent A (%) 100 95 82 70 70 0 0 
Sovent B (%) 0 5 18 30 30 100 100 
Solvent A: H2O, 0.1% (v/v) trifluoroacetic acid 
Solvent B: Acetonitrile, 0.1% (v/v) trifluoroacetic acid 
Flow rate: 1 ml/min 
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Figure 2.3. Transition Ions for Multiple Reaction Monitoring (MRM) of 
CML, Pentosidine, Argpyrimidine and Pyridylethyl-Cysteine. 
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          CML, pentosidine and argpyrimidine standards were injected together with 
the PEC internal standard on the Hypercarb™ column. All of the standards were 
separated well in the chromatography in the absence of a plasma hydrolysate 
(Figure 2.4). CML eluted at 7.26 min, at ~ 4.4% solvent B, PEC eluted at 8.82 
min, ~ 7.8% solvent B, and argpyrimidine and pentosidine eluted at 13.12 min 
and 14.62 min, respectively, with isocratic 30% solvent B. These standards 
spiked with plasma hydrolysate   (~ 8 mg protein) (Figure 2.5) resulted in shifted 
retention times for CML and pentosidine while argpyrimidine and PEC remained 
largely unchanged. This caused argpyrimidine and pentosidine to co-elute. In 
addition, numerous fluorescent substances co-eluted with argpyrimidine and 
pentosidine. A second chromatography step was incorporated to positively 
identify all compounds of interest. 
Table 2.5. Mass Spectrometric Multiple Reaction Monitoring Detection  
Analyte 
Parent ion 
(Q1)    
m/z (Da) 
Fragment 
ion (Q3)    
m/z (Da) 
DP*   
(Volts) 
FP*   
(Volts) 
CE*    
(Volts) 
CML 205.1 84.1 35 250 26 
Pentosidine 379.2 187.2 40 300 45 
Argpyrimidine 255.2 237.3 35 250 20 
Pyridylethyl-Cysteine 
(Internal Standard) 227.3 106.1 25 250 27 
* DP, Declustering Potential; FP, Focusing Potential; CE, Collision Energy. 
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Figure 2.4. HPLC System I Separation of CML, Argpyrimidine and 
Pentosidine Standards and PEC (internal standard) on a Hypercarb™ 
Column in the Absence of a Plasma Hydrolysate. 
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Figure 2.5. HPLC System I Separation of CML, Argpyrimidine and 
Pentosidine Standards and PEC (internal standard) on a Hypercarb™ 
Column in the Presence of Plasma Hydrolysates. 
 59 
 
          For experimental analyses, plasma hydrolysate (40 µl, ~ 8 mg protein) was 
spiked with 15 pmol of PEC standard and separated on HPLC System I. Three 
fractions were collected: CML was collected from 4.2 to 6.0 min (~ 1.8 ml); 
argpyrimidine and pentosidine were collected in the same fraction from 12.0 to 
13.8 min (~ 1.8 ml); and PEC was collected from 8.4 to 9.0 min (~ 600 µl). 
Fractions from HPLC System I were vacuum dried and stored at - 80ºC until 
further analysis. 
          HPLC System II: Chromatography fractions from HPLC System I were         
re-fractionated on HPLC System II using a Cogent Diamond Hydride™ Column 
(4.2 µm particles, 150 × 2.1 mm). The Cogent Diamond Hydride™ column is a 
silica hydride-based stationary phase that separates very polar compounds in 
aqueous normal phase (Pesek et al., 2008). Two mobile phases were used in 
HPLC System II to optimize the resolution of each analyte of interest. Fractions 
containing CML were re-chromatographed using aqueous acetic acid/acetonitrile 
solutions (Table 2.6) and CML was detected and quantified by tandem MS, using 
MRM at 205.1 / 84.1 m/z and the same parameters as in HPLC System I (except 
the ionization source temperature was 490°C). Calibration curves with the CML 
standard were prepared at five levels: 10, 20, 30, 40, 50 pmol. Quantification of 
CML was based on peak area and the external standard calibration curve.  
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          HPLC System I chromatography fractions containing PEC, argpyrimidine 
and pentosidine were re-chromatographed using ammonium acetate/acetonitrile 
solvents and gradient separation (Table 2.7). HPLC separation was couple with 
fluorescence detection followed by tandem MS as for CML. PEC was monitored 
by MRM at 227.3 / 106.1 m/z using the same mass spectrometry conditions as in 
Table 2.5 and the calibration curve developed with five amounts: 3, 6, 9, 12, 15 
pmol. Pentosidine and argpyrimidine were monitored using fluorimetry (λex / λem = 
335/385 nm) coupled with MRM mass spectrometry (pentosidine using 379.2 / 
187.2 m/z; argpyrimidine using 255.2 / 237.3 m/z) and calibration curves 
developed at 2, 4, 6, 8, 10 pmol. The mass spectrometric signal for pentosidine 
was less sensitive and less stable than the fluorescent signal, therefore the 
quantification of pentosidine was based on the fluorescence peak area and the 
external standard calibration curve. 
Table 2.6. Gradient Profile for CML on the Cogent Diamond Hydride™ 
Column in HPLC System II 
Analysis Time (min) 0 3 5 7 8 11.5 13.6 
Sovent A (%) 5 5 45 45 52 52 100 
Sovent B (%) 95 95 55 55 48 48 0 
Solvent A: H2O, 0.1% (v/v) acetic acid 
Solvent B: Acetonitrile, 0.1% (v/v) acetic acid 
Flow rate: 400 µl/min 
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2.6  Quantification of CEP Adducts and CEP Autoantibody 
          Competitive ELISA was performed by Dr. Jiayin Gu to determine CEP 
adduct concentrations in AMD and control plasma as described elsewhere (Gu et 
al., 2003; Gu et al., 2009). Briefly CEP-BSA was used as coating agent and 
CEP-HSA as reference standard, and purified rabbit anti-CEP polyclonal 
antibody (pAb) as primary antibody.  The reference standard curve was 
generated by ten serial dilutions of CEP-HSA with initial pyrrole concentration 
8692.5 pmol/mL and a 0.2 serial dilution factor.  Sample plasma was also serial 
diluted with PBS and a 0.2 dilution factor.  Up to 6 dilutions were made for each 
plasma sample.   
          Direct ELISA was performed by Dr. Jiayin Gu to determine anti-CEP 
autoantibody titer in AMD and control plasma (Gu et al., 2003; Gu et al., 2009). 
Plasma samples were diluted 10 times and added to 3 CEP-BSA coated wells 
and 3 BSA coated wells. The titer was calculated as the ratio (A/A0) of the mean 
Table 2.7. Gradient Profile for PEC, Pentosidine and Argpyrimidine on 
the Cogent Diamond Hydride™ Column in HPLC System II 
Analysis Time (min) 0 0.5 3 13 15 
Sovent A (%) 0 10 10 90 100 
Sovent B (%) 100 90 90 10 0 
Solvent A: H2O, 10 mM ammonium acetate, pH 6.0 
Solvent B: 80% (v/v) ACN, 10 mM ammonium acetate, pH 6.0 
Flow Rate: 400 µl/min 
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absorbance of 3 CEP-BSA coated wells (A) vs the mean absorbance of 3 BSA 
coated wells (A0). 
 
2.7  Statistics 
          Continuous measures were summarized using means, standard deviations, 
medians and interquartile ranges. Differences in plasma CML and pentosidine 
concentrations between control and AMD patients were evaluated using two 
sample t-tests in Excel 2003 (Microsoft® Office). To evaluate the relationship 
between CML and pentosidine with AMD susceptibility, a logistic regression 
model was fit with both variables as predictors using SAS 9.1 software (SAS 
Institute, Cary, NC). C-statistics measured the model’s ability to discriminate 
between AMD and controls, and odds ratios (ORs) showed the change in risk of 
AMD based on the predictors. ORs, c-statistics and p-values were determined 
based on log-transformed marker concentrations. Validation of c-statistics was 
performed using 2000 bootstrap (random) resamplings to calculate empirical 
95% confidence intervals (CI) and by performing 10-fold cross-validation. P-
values < 0.05 were considered significant. Sensitivity and specificity were 
calculated to maximize the sum of the two values using receiver operating 
characteristic (ROC) curves constructed with SAS 9.1 from the output of logistic 
regression analysis fit with either single AGE marker or CEP adducts, or the 
combination of the AGE markers and CEP adducts. C-statistics and p-values 
comparing ROC curves were determined with SAS 9.1. For association analyses 
of combined effects of plasma AGEs with CEP adducts, ORs with 95% CI and 
 63 
 
Fisher Exact p-values were calculated with SAS 9.1 software. Pearson’s 
correlation analysis in Minitab Release 15 (Minitab Inc., PA) was used to 
compare concentrations of AGE markers with plasma donor age.  
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CHAPTER III 
RESULTS 
 
 
 
3.1 Plasma Protein Quantification 
          Vapor phase HCl hydrolysis was performed to cleave the proteins into 
amino acids and sixteen of the common twenty amino acids were quantified by 
PTC Amino Acid Analysis and by AccQ•Tag™ Amino Acid Analysis. Quantified 
amino acids include Asp, Glu, Ser, Gly, His, Arg, Thr, Ala, Pro, Tyr, Val, Met, Ile, 
Leu, Phe, and Lys. Trp and Cys are destroyed by HCl hydrolysis, Ser and Thr 
are partially destroyed, Ile and Val are slow to cleave, Met is subject to oxidation, 
and Asn and Gln are deamidated.  
          Protein Quantification by PTC Amino Acid Analysis. Replicate PTC amino 
acid analyses were performed on plasma protein hydrolysates using standard H 
(Pierce) for calibration and hydrolysates of NBS-BSA for quantitative validation of 
the entire procedure (Figure 3.1). The average peak area was calculated for
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each amino acid from multiple injections of Standard H amino acids and 
response factors were calculated for each amino acid by dividing the average 
peak area by pmole of amino acid. PTC amino acid analysis yielded average 
relative standard deviations (RSD) of 0.25% for retention time and 5.02% for 
response factors for n = 6 replicates of Standard H amino acids performed eight 
times over 14 days (Table 3.1). The amount of protein in plasma hydrolysates 
and NBS-BSA hydrolysates was obtained by dividing the peak area from each 
amino acid by the response factors determined by calibration.  
          Protein Quantification by AccQ•Tag™ Amino Acid Analysis. Replicate 
AccQ•Tag™ amino acid analyses were performed on plasma protein 
hydrolysates using standard amino acids (Thermo Scientific) for calibration and 
NBS-BSA hydrolysates to validate quantification. Calibration was achieved by 
analyzing AccQ•Tag™ derivatized amino acid standards (Figure 3.2) at six 
different amounts (1-50 pmol) in 3 replicates each. Reproducibility of retention 
times and the linearity of the calibration curves for each amino acid are shown in 
Table 3.2. AccQ•Tag™ Amino Acid Analysis yielded average RSDs of 0.18% for 
retention times and 5.1% for response factors in n = 6 replicates of amino acid 
standards performed twelve times over 20 days. The amount of protein in plasma 
protein and NBS-BSA hydrolysates was determined by dividing peak areas by 
response factors. 
          Examples of quantitative results from PTC amino acid analysis of NBS-
BSA and plasma protein hydrolysates are shown in Table 3.3 and 3.4, 
respectively. Both PTC and Waters AccQ•Tag™ derivatized amino acid analysis 
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were performed in duplicate for each plasma protein sample, and the results are 
presented in Table 3.5 and 3.6, respectively. The quantitative results agree well 
and difference in protein quantification for the two methods was less than 10% 
(Table 3.7). Since carboxymethyllysine, argpyrimidine and pentosidine are 
glycation modifications of arginine and lysine, the concentration of arginine (R) 
and lysine (K) were also quantified in Table 3.8.  
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Figure 3.1. PTC Amino Acid Analysis—Representative Chromatography.  
A: Standard H Amino Acids (480 pmol); B: NBS-BSA hydrolysate (2.2 µg 
analyzed); C: Plasma protein hydrolysate (1.2 µg analyzed). 
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Figure 3.2. AccQ•Tag™ Amino Acid Analysis — Representative 
Chromatography. A: Standard amino acids (10 pmol); B: NBS-BSA 
hydrolysate (36.7 ng analyzed); C: Plasma protein hydrolysate (39.2 ng 
analyzed). * Derivatization byproducts. 
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Table 3.1. Reproducibility of Retention Times and Response Factors in 
PTC Amino Acid Analysis. Sample = Standard H Amino Acids (480 pmol) 
(Pierce), n = 48 analyses over 14 days. 
Amino 
acids 
Retention Time 
(min) RSD 
Response Factor 
(×10-1) RSD 
ASP    (D) 3.12 0.55% 1.08 11.99% 
GLU    (E) 3.40 0.52% 1.27 8.05% 
SER    (S) 4.34 0.41% 1.34 4.47% 
GLY    (G) 4.77 0.39% 1.55 4.01% 
HIS     (H) 5.61 0.42% 1.32 4.97% 
ARG    (R) 6.38 0.33% 1.16 7.25% 
THR    (T) 6.66 0.30% 1.29 3.11% 
ALA    (A) 6.86 0.28% 1.62 3.04% 
PRO    (P) 7.46 0.25% 1.72 3.09% 
TYR    (Y) 11.92 0.10% 1.57 3.88% 
VAL    (V) 12.64 0.08% 1.48 3.78% 
MET    (M) 13.00 0.08% 1.52 2.91% 
ILE      (I) 14.93 0.08% 1.51 3.88% 
LEU     (L) 15.17 0.07% 1.71 7.93% 
PHE     (F) 16.53 0.07% 1.53 3.42% 
LYS     (K) 18.30 0.11% 2.85 4.47% 
 Average 0.25% Average 5.02% 
*RSD = Relative Standard Deviation 
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          Furosine was quantified in each plasma protein sample using AccQ•Tag™ 
amino acid analysis (Figure 3.3) and the results are presented in Table 3.9. 
Furosine contains a primary and a secondary amino group (Figure 1.11) and 
both are derivatized by the AccQ•Tag™ reagent, yielding two different mono-
derivatized forms and a di-derivatized form. As shown in Figure 3.3, furosine 
peaks 1 and 2 exhibit relatively close retention times (7.1 min and 7.2 min); these 
peaks may represent the mono-derivatized forms of furosine. Furosine peak 3 
elutes much later, is less polar than peaks 1 and 2 and therefore may be the     
di-derivatized form of furosine. Different amounts of furosine (2 to 10 pmol) were 
derivatized, the peak areas of furosine peaks 1, 2 and 3 were integrated, and the 
response factors for each peak found to be constant under the derivatization 
conditions used. Furosine peaks 1 and 2 overlapped with Ile and Leu and 
therefore could not be used for quantification. Furosine peak 3 was well 
separated from other amino acids and was therefore used for quantification of 
furosine in plasma protein hydrolysates. The low concentration of furosine in 
plasma required a relatively large amount of plasma hydrolysate to detect 
furosine in the analysis. Plasma protein concentration was calculated based on 
select amino acids in the plasma protein hydrolysate (as described in methods) 
including H, R, G, D, E, A, P, K, Y, V, F. Those residues yielding amounts within 
±15% of the mean were used for protein quantification. Usually protein 
quantification for the furosine analyses was based on 5 or 6 residues (H, R, P, Y, 
V, F). The protein concentration of all samples during the furosine analysis was 
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quantified in good agreement with the previous results shown in Table 3.6 
(average difference ~ 1.7%, n = 90).   
          The average concentration of furosine in the normal control samples (n = 
30) was 1.03 ± 0.11 pmol/µg, which is very close to 1.05 ± 0.11 pmol/µg 
determined for all the AMD samples (n = 60). Among all the AMD patients, there 
were five diabetic patients and the average furosine concentration for these 
samples was 1.24 ± 0.05 pmol/µg, ~ 20% higher than the controls (Figure 3.4). 
There was no apparent difference in furosine concentration between the control 
donors and AMD patients without diabetes (n = 55, 1.03 ± 0.09 pmol/µg). Overall, 
the results for furosine showed minimal if any unknown diabetic patients in our 
study population. 
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Figure 3.3. Representative Chromatography for Quantification of 
Furosine using AccQ•Tag™ Amino Acid Analysis. A: Standard amino 
acids (10 pmol); B: Furosine standard (5 pmol); C: Furosine (~ 4.2 pmol) was 
quantified in plasma hydrolysate (2.7 µg). The acetonitrile gradient was 
modified to optimize resolution of furosine peak 3. * Derivatization byproducts. 
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Figure 3.4. Quantification of Furosine in Plasma Protein Samples. 
Furosine was quantified by AccQ•Tag™ amino acid analysis from control (n = 
30) and AMD (n = 60) plasma donors, including non-diabetes (n = 55) and 
diabetes (n = 5) are shown with mean (Δ) results ± standard deviation (SD) 
and with median (○) results ± first and third quartiles (Q1, Q3). The data is 
presented in Table 3.9. P-values (two sided t-Test) were determined from log-
transformed concentrations. 
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3.2 Quantification of AGEs in Plasma Hydrolysate 
          Plasma protein hydrolysates were assayed for AGEs by a two-step HPLC 
process. Only protein-bound AGEs were analyzed as free AGEs were washed 
away during acetone precipitation of the plasma proteins. A representative 
chromatography from HPLC System I (Figure 3.5) shows that CML and the 
internal standard (PEC) are well resolved but that argpyrimidine and pentosidine 
co-elute. Therefore, fractions collected from HPLC System I were re-
chromatographed in HPLC System II (Figure 3.6 and 3.7) to separate 
argpyrimidine and pentosidine (Figure 3.8). Argpyrimidine in plasma hydrolysates 
was at or below the detection limits of the analytical system and therefore 
quantification of the AGEs was not pursued further. Representative calibration 
curves for CML, pentosidine and PEC (internal standard) are shown in Figure 3.9. 
Excellent linearity was observed between peak area and amount analyzed for all 
three amino acids. The amount of CML, PEC and pentosidine were calculated 
with the integrated peak area and the external calibration curve. The recovery of 
PEC on two HPLC systems was calculated by dividing the final amount detected 
in the HPLC System II by the original 15 pmol added into the plasma hydrolysate 
before the injection on HPLC System I. The average recovery of the PEC was 
70.1% ± 0.13 (mean ± SD, n = 90). The measured amounts of CML and 
pentosidine were corrected based on the recovery of PEC. The amounts of CML, 
pentosidine and PEC found in each plasma protein hydrolysate are presented in 
Table 3.10.  
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Figure 3.5. HPLC System I Representative Chromatography of CML, 
Argpyrimidine and Pentosidine Standards and PEC (internal standard) in 
the Presence of Plasma Hydrolysates. 
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Figure 3.6. HPLC System II Representative Chromatography of CML in 
Acetic Acid/Acetonitrile Solvents. (A) CML standard (20 pmol); (B) CML 
from HPLC System I fractions from a normal control subject; (C) CML from 
HPLC System I fractions from an AMD patient. Detection: mass spectrometry 
using multiple reaction monitoring (MRM) at 205.1 / 84.1 m/z, and an 
ionization source temperature of 490°C. 
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Figure 3.7. HPLC system II Representative Chromatography of PEC in 
Ammonium Acetate/Acetonitrile Solvents. (A) PEC standard (6 pmol); (B) 
Spiked PEC from HPLC System I fractions from a normal control subject; (C) 
Spiked PEC from HPLC System I fractions from an AMD patient. Detection: 
mass spectrometry using multiple reaction monitoring (MRM) at 227.3 / 106.1 
m/z, and an ionization source temperature of 490°C. 
 86 
 
Figure 3.8. HPLC System II Representative Chromatography of 
Pentosidine and Argpyrimidine in Ammonium Acetate/Acetonitrile 
Solvents. (A) Pentosidine standard (4 pmol); (B) Argpyrimidine standard (8 
pmol); (C) Pentosidine and argpyrimidine fractions from HPLC System I from a 
normal control subject; (D) Pentosidine and argpyrimidine fractions from HPLC 
System I from an AMD patient. Detection: fluorimetry at 335 nm excitation, 385 
nm emission using Waters™ 474 Scanning Fluorescence Detector.  
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Figure 3.9. Representative Standard Calibration Curves for CML, 
pentosidine and PEC on HPLC System II. ESI MRM, electrospray ionization 
mass spectrometry multiple reaction monitoring, was used for detection of 
CML at 205.1 / 84.1 m/z and PEC at 227.3 / 106.1 m/z. Each standard mixture 
was analyzed in triplicate on each analysis day. 
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3.3 Elevated CML and Pentosidine in AMD Plasma 
          Plasma from a total of 30 control subjects and 60 AMD subjects were 
analyzed for CML and pentosidine by LC-MS and LC-fluorimetry, including 30 
patients with early-stage dry AMD (AMD Category 2) and 30 patients with 
advanced-stage AMD (AMD Category 4). Overall, AMD patients (n = 60) 
exhibited higher CML (~ 1.6x) and pentosidine (~ 1.8x) (p-values < 0.0001) 
compared with the control plasma (Figure 3.10 and Table 3.11). Correlation 
between CML and pentosidine concentrations shows that significantly more 
donors with both CML and pentosidine elevated were apparent in AMD patients 
than in the controls. Higher mean levels of CML (1.4x – 1.7x) and pentosidine 
(1.6x – 1.9x) were observed in both early-stage and advanced AMD patients 
relative to control plasma (p-values < 0.001) (Figure 3.11 and Table 3.11). 
Comparing Category 2 to Category 4 AMD patients, CML was elevated ~ 10% 
(p-value = 0.30) and pentosidine was elevated ~ 20% (p-value = 0.09) in 
advanced-stage AMD patients, however these differences were not statistically 
significant (Figure 3.11 and Table 3.11). 
          Logistic regression modeling of the CML data from all control and AMD 
donors yielded a c-statistic equal to 0.80 for AMD patients (Table 3.12), 
supporting a 80% likelihood that a randomly selected person with elevated CML 
will be an AMD case rather than a control. Similar logistic regression modeling of 
the pentosidine data yielded a c-statistic equal to 0.92 (Table 3.12), supporting a 
92% likelihood that a randomly selected person with elevated pentosidine will be 
an AMD case. Small difference in c-statistics for CML (0.74 - 0.85) and for 
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pentosidine (0.90 - 0.94) were observed from early AMD and advanced-stage 
AMD (Table 3.12) with slightly higher values obtained for advanced stage 
disease. Bootstrap resampling and 10-fold cross-validation verified all c-statistics 
and 95% CIs. The predicted risk of AMD was estimated by odds ratio (OR) for 
donors with elevated CML and pentosidine relative to the median levels in control 
plasma (Table 3.11). The large confidence intervals associated with the ORs 
indicate that the OR values lack precision. Additional donor plasma must be 
analyzed to improve the precision of the OR estimates. 
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Figure 3.10. Carboxymethyllysine (CML) and Pentosidine are Elevated in 
AMD Plasma. CML (A) and pentosidine concentrations (B) were quantified by 
LC-MS and LC-fluorimetry from control (n = 30) and AMD (n = 60) plasma 
donors are shown with mean (Δ) results ± standard deviation (SD) and with 
median (○) results ± first and third quartiles (Q1, Q3). For all AMD patients (n 
= 60), the mean concentration of CML was 42.7 ± 14.9 pmol/mg and 
pentosidine was 1.65 ± 0.52 pmol/mg. P-values (two sided t-Test) were 
determined from log-transformed concentrations. This data was presented in 
Table 3.10 and 3.11 with odds ratios and 95% confidence intervals. 
Correlation between CML and pentosidine concentrations are shown for the 
control (C) and AMD (D) cohorts with horizontal and vertical dashed lines 
indicating median control values. Significantly more donors with both CML and 
pentosidine elevated are apparent in AMD patients than in the controls (upper 
right quadrants in C and D). 
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3.4 AMD Risk Based on Multiple Markers 
          Another oxidative protein modification identified as an AMD biomarker is    
2-(ω-carboxyethyl)pyrrole (CEP). CEP modifications are generated by covalent 
adduction of primary amino groups with 4-hydroxy-7-oxohept-5-enoic acid 
(HOHA), an oxidation fragment derived uniquely from docosahexaenoic acid 
(DHA)-containing phospholipids (Crabb et al., 2002). CEP adducts and CEP 
autoantibody were quantified by competitive ELISA in the same control plasma (n 
= 30) and AMD plasma (n = 56) (Table 3.13), that were analyzed for CML and 
pentosidine. Higher mean levels of CEP adducts (~ 2x) were found in AMD 
plasma (p-value < 0.0001) (Figure 3.12). CEP autoantibody was also elevated ~ 
30% compared with the normal control (p-value = 0.25) (Figure 3.12), however, 
the elevation of CEP autoantibody in AMD patient was not significant, so CEP 
autoantibody values were not used in the statistical analysis. Comparison of CEP 
adducts, CEP autoantibody, CML and pentosidine levels in control and AMD 
plasma are presented in Figure 3.12. The relative standard deviation (RSD) of 
CEP adduct and CEP autoantibody values from ELISA quantification was 52.1% 
and 70.0%. For the quantification of CML and pentosidine using LC-MS and LC-
fluorimetry, the RSD of the average values was 35.8% and 23.8%, respectively. 
Notably, the chromatography assays for CML and pentosidine exhibit less 
variability compared with the ELISA for CEP.  
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Figure 3.12. CEP Adducts, CEP Autoantibody, CML and Pentosidine are 
Elevated in AMD Plasma. CEP adducts (pmol/ml) and CEP antoantibody titer 
were quantified in plasma by ELISA in control (n = 30) and AMD patients (n = 
56). CML and pentosidine were quantified by LC-MS and LC-fluorimetry from 
control (n = 30) and AMD (n = 60) plasma donors. The mean (Δ) results ± 
standard deviation (SD) and the median (○) ± first and third quartiles (Q1, Q3) 
are shown. For AMD patients, the mean concentration of CML was 2.07 ± 0.70 
nmol/ml, pentosidine was 79.5 ± 23.1 pmol/ml, CEP adduct was 44 ± 22 
pmol/ml, and CEP autoantibody was 1.8 ± 1.2. P-values (two sided t-Test) 
were determined from log-transformed concentrations. 
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          Correlation of CEP adducts, CML and pentosidine is shown in Figure 3.13.  
All three oxidative protein modifications were correlated closely, with 75% to 87% 
elevated above median control levels in AMD patients compared with only 23% 
to 27% elevated in control donors. When considered together as markers for 
AMD, pentosidine and CML yielded an OR for AMD of 21.4 (95% CI, 6.9, 65.9), 
CML and CEP adducts yielded an OR for AMD of 9.9 (95% CI, 3.5, 27.9), 
pentosidine and CEP adducts yielded an OR for AMD of 9.1 (95% CI, 3.3, 25.2). 
Again the large 95% confidence intervals indicate these OR values lack precision 
and additional plasma must be analyzed to improve precision. 
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          Sensitivity and specificity measures were determined with receiver 
operating characteristic (ROC) curves from all AMD cases and controls for CML, 
pentosidine and CEP adducts alone, and for the combined markers (Table 3.14). 
Calculated to maximize the sum of the two values, sensitivity was greater for 
CML (83%) and pentosidine (85%) alone than for CEP (68%) alone. The 
specificity of pentosidine (93%) and CEP (87%) alone were higher than that for 
CML alone (73%). The p values for the comparison of c-statistics of single 
markers demonstrated that there was no significant difference for CEP compared 
with CML and for pentosidine compared with CEP. But there was significant 
difference in the c-statistics between CML and pentosidine, which suggests that 
pentosidine has a higher discrimination accuracy than CML. The combination of 
CML and pentosidine improved specificity to 95% with 83% sensitivity; the 
combination of CML and CEP adducts improved specificity to 93% with 71% 
sensitivity; and the combination of pentosidine and CEP adducts improved 
specificity to 95% with 86% sensitivity. The area under the ROC curve (c-statistic) 
is a measure of the discriminating accuracy of these markers and was verified by 
bootstrap resampling and by 10-fold cross-validation. Pentosidine levels 
exhibited the largest c-statistics and alone could discriminate between AMD and 
control plasma with 92% accuracy and with 95% accuracy in combination with 
CEP adducts. The p values here indicate that c-statistics of the combined 
markers and the single marker are not significantly different, except for possibly 
combined CML and pentosidine versus CEP alone (p-value = 0.06). 
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3.5 The Influence of Age on Plasma CML and Pentosidine Levels 
          Study population characteristics are summarized in Table 3.15, including 
age, gender, race, smoking status and health history. Comparison of plasma 
AGE levels by donor age (Figure 3.14) revealed that CML concentrations are 
increased gradually with age in both control and AMD donors (Figure 3.14A), and 
AMD patients exhibit significantly higher mean levels of CML than controls at all 
ages (Figure 3.14B). Mean pentosidine remained stable with age in controls, but 
increased gradually with age in AMD donors (Figure 3.14C) and was higher than 
in controls at all age (Figure 3.14D). 
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Table 3.15. Characteristics of Study Population 
Control AMD Category 2 
AMD 
Category 4 Property Category 
n=30 n=30 n=30 
Age (year)     
 Mean ± SD 72 ± 5 74 ± 10 73 ± 5 
 Range 64 - 80 56 - 91 64 - 89 
Gender     
 Male 15 (50.0%) 15 (50.0%) 15 (50.0%) 
 Female 15 (50.0%) 15 (50.0%) 15 (50.0%) 
Race     
 Caucasian 30 (100%) 30 (100%) 30 (100%) 
Smoking Status    
 Non-smoker 28 (93.3%) 24 (80.0%) 29 (96.7%) 
 Smoker 2 (6.7%) 6 (20.0%) 1 (3.3%) 
Health History    
 Hypertension 21 (70.0%) 15 (50.0%) 19 (63.3%) 
 Hyperlipidemia 15 (50.0%) 15 (50.0%) 9 (30.0%) 
 Diabetes 0 (0.0%) 3 (10.0%) 2 (6.7%) 
  Cardiovascular disease 6 (20.0%) 8 (26.7%) 4 (13.3%) 
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Figure 3.14. CML and Pentosidine Plasma Levels by Donor Age. (A) CML 
and (C) pentosidine levels in the control (grey) and AMD (red) study 
populations are shown plotted by donor age. Pearson’s correlation analysis 
(horizontal color coded lines and p-value from log-transformed data) revealed 
gradual increases in CML with age. Pentosidine in AMD donors also gradually 
increased with age, while in control donors the level of pentosidine was stable 
with age. (B) CML and (D) pentosidine levels in control and AMD donors are 
plotted by age group, including 51-60 y (AMD n = 4), 61-70 y (control n = 12, 
AMD n = 18), 71-81 y (control n = 18, AMD n = 28), ≥ 81 y (AMD n = 10). Fold 
difference in CML and pentosidine concentrations is indicated between the 
control and AMD groups. Asterisks reflect p-values from a two sample t-test 
(*** p < 0.001, ** p < 0.01, * p < 0.05). 
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3.6 The Influence of Gender and Health Factors on Plasma CML and  
      Pentosidine 
          Plasma CML and pentosidine concentrations were compared by gender 
and health history, including smoking, hypertension, hyperlipidemia, diabetes and 
cardiovascular disease (Figure 3.15). For each comparison, significant 
differences in CML and pentosidine concentrations were observed between AMD 
and control donors. No statistically significant differences in CML concentrations 
were detected within the AMD or control cohorts. Small but significant differences 
were detected in pentosidine levels within the AMD cohorts. Specifically, in AMD 
patients, mean pentosidine levels were higher in donors with hypertension and 
cardiovascular disease. Notably, these comparisons provide preliminary results 
because of the relatively low number of donors analyzed. 
          From the data shown in Table 3.9 and Figure 3.4, 3 control (C-1, C-10, C-
18) and 2 AMD samples (A2-10, A4-7) may be considered as suspect diabetics 
based on furosine concentrations greater than the diabetic mean – 1 SD (≥ 1.19 
pmol/mg). However, the medical records for these patients provided no 
indications that any were diabetics. Notably none of these patients exhibited 
furosine concentrations greater than the control mean + 2 SD (≥ 1.25 pmol/mg). 
The quantification of furosine confirmed that there were no unknown diabetes in 
our study group. 
          Both CML and pentosidine have been reported to increase in diabetes 
(Goh et al., 2008). In our study group, CML and pentosidine concentrations in the 
five patients that were both AMD and diabetic (A2-5, A2-16, A2-23, A4-13, A4-17) 
 106 
 
were less than 1 SD from mean concentrations (Table 3.10), except for A2-16 
which exhibited very high pentosidine but somewhat reduced CML. The three 
control suspect diabetics (C-1, C-10, C-18) showed no significant difference in 
CML and pentosidine concentrations compared with the mean of other normal 
controls. The two AMD suspect diabetics (A2-10, A4-7) also have CML and 
pentosidine concentrations within 1 SD of the AMD mean concentrations (Table 
3.10). Notably, AMD patient A4-28 exhibited the highest CML and pentosidine 
concentrations but showed a furosine concentration that was not elevated (Table 
3.9). These data demonstrate that the elevated levels of CML and pentosidine in 
plasma were associated with AMD pathology and not diabetes. 
          CEP adduct concentrations in the four diabetic AMD patients (A2-16, A2-
23, A4-13, A4-17) were less than 1 SD from the mean concentrations (Table 
3.13). CEP adduct levels in the control and AMD suspect diabetics showed no 
significant difference compared with group mean concentrations (Table 3.13). 
Notably, AMD patient A4-8 exhibited the highest CEP adducts concentration but 
showed a furosine concentration within 1 SD from the mean concentration (Table 
3.9). The results showed that the elevated levels of CEP adducts in plasma were 
associated with AMD but not diabetes, which is consistent with results from the 
previous studies (Gu et al., 2009). 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 
 
 
4.1 Discussion 
          Extracellular and intracellular proteins can be modified by non-enzymatic, 
oxidative glycosylation to form advanced glycation end-products (AGEs) (Maillard 
et al., 1912; Glomb et al., 2001). Significant targets of glycation modifications are 
collagens, which are major components of extracellular matrices, such as 
Bruch’s membrane (Johnson et al., 2004). Previous immunohistochemical 
studies have demonstrated the existence of AGEs in Bruch’s membrane, drusen 
and retinal pigment epithelium (RPE) (Ishibashi et al., 1998; Handa et al., 1999; 
Crabb et al., 2002; Glenn et al., 2009). The high light exposure and high oxygen 
tension in the retina provide a permissive environment for oxidation, including 
oxidative glycation of intracellular proteins in the RPE and extracellular proteins 
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in the adjacent Bruch’s membrane (Sarks et al., 1999; Crabb et al., 2002). With 
the choriocapillaris adjacent to Bruch’s membrane and with the RPE serving as a 
blood-retinal barrier, AGEs formed in the RPE and Bruch’s membrane may also 
find their way into the blood stream. The accumulation of oxidative modifications 
in Bruch’s membrane and drusen have been proposed to be catalyst of AMD 
pathology (Crabb et al., 2002; Gu et al., 2003; Ebrahem et al., 2006; Gu et al., 
2009).  
          AGEs exacerbate disease progression through two general mechanisms: 
modifying molecules and forming nondegradable, cross-linked aggregates, thus 
impairing normal tissue functions, and altering cellular function directly through 
receptor-mediated activation (Howes et al., 2004). Cross-linking of long-lived 
extracellular matrix proteins in Bruch’s membrane and the inability of RPE cells 
to degrade AGE intracellularly contributes to impaired cellular physiology. It is 
important to note that AGEs, in addition to their established role in damaging 
protein function, could act as important instigators of retinal disease by provoking 
pro-inflammatory cascades that are modulated by key receptors expressed by 
retinal cells. In the context of the outer retina, studies have established that the 
receptor for AGEs (RAGE) is expressed on RPE cells and that receptor levels 
are significantly increased in AMD, especially on cells adjacent to drusen 
(Yamada et al., 2006). RAGE can be upregulated with aging and disease, and 
induces a pathologic response through several signal transduction pathways 
(Schmidt et al., 2001). RAGE forms a complex on the plasma membrane, which 
is thought to endocytose AGE-modified proteins as a protective response 
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(Vlassara et al., 1995). The RAGE complex on plasma membrane can regulate 
the diffusion of AGEs between RPE cells and the choriocapillaris. We 
hypothesize that the plasma concentrations of AGEs in AMD may reflect the 
accumulation of AGEs in RPE and Bruch’s membrane, and therefore be useful 
for accessing AMD susceptibility. 
          Advanced glycation end-products accumulate during aging, especially in 
choriocapillaris and Bruch’s membrane (Handa et al., 1999), and are highly 
expressed in CNV membrane (Ishibashi et al., 1998). Several studies have 
shown that AGEs stimulate the proliferation of choroidal endothelial cells, the 
expression of matrix metalloproteinase type 2, the upregulation of growth factors 
such as VEGF, and angiogenesis in vivo (Hoffmann et al., 2002). Accordingly, 
they may be important promoters of CNV in exudative AMD. 
          We quantified the plasma protein concentrations of two advanced glycation 
end-products, namely CML and pentosidine, both of which are chemical 
modifications of protein lysine. The results from this study showed that mean 
levels of CML and pentosidine were significantly elevated in AMD plasma. To be 
exact, the mean CML concentration was ~ 60% higher in AMD patients (p < 
0.0001) than in healthy control patients. Similarly, the mean pentosidine level in 
AMD patients was found to be elevated ~ 80% relative to the control donors (p < 
0.0001). In our study group, AMD patients exhibited either early-stage dry AMD 
(AMD Category 2) (n = 30) or advanced-stage AMD (AMD Category 4) (n = 30). 
These preliminary results showed no significant differences in plasma 
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concentrations of CML and pentosidine between patients from AMD categories 2 
and 4. 
          Statistical analyses were pursued to evaluate the effectiveness of plasma 
protein CML and pentosidine as AMD biomarker. The estimated odds ratios for 
CML (9) and pentosidine (11) suggest high potential for evaluating AMD risk, 
however, the large 95% confidence intervals surrounding these estimates 
indicate that the values lack precision and more studies are needed to refine this 
statistic. C-statistics were used to evaluate the likelihood that a randomly 
selected person will be an AMD case rather than a control based on elevated 
plasma protein CML or pentosidine. As single markers, pentosidine concentration 
provided ~ 92% discrimination accuracy, and CML provided ~ 80% accuracy. 
This suggests that pentosidine will be the more powerful and efficient in 
predicting AMD susceptibility. 
          The effectiveness of CML and pentosidine biomarkers to predict AMD 
susceptibility was compared with that of CEP adducts, an oxidative modification 
generated uniquely from DHA phospholipids and elevated in AMD plasma (Gu et 
al., 2009). Elevated CEP adducts in our study population provided ~ 81% 
accuracy in predicting AMD alone, very similar to that of CML (~ 80% accuracy). 
Using CEP-adducts and CML together provided ~ 89% accuracy, while CEP-
adducts and pentosidine together provided ~ 95% accuracy in discriminating 
AMD patients from normal controls. 
          Both CML and pentosidine exhibit significantly higher mean levels in AMD 
than controls at all ages analyzed. The demographic results showed that 
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elevated CML was correlated with age in both controls and AMD donors. 
However, elevated pentosidine was only correlated with age in AMD donors, and 
remains relatively stable with age in control donors. This is consistent with 
previous reports of age-dependent increases in AGEs accumulation, and 
suggests that AGEs may play important roles in age-related pathologies (Sell et 
al., 1990; Brownlee et al., 1995). For example, AGEs likely contribute to the age-
related structural and physiological changes in Bruch’s membrane, including an 
increase in overall thickness (Okubo et al., 1999; Zarbin et al., 2004; Glenn et al., 
2009). 
          Previous studies have shown that diabetes may induce elevated plasma 
CML and pentosidine. For example, in diabetic patients plasma CML 
concentrations have been reported to be 1.92 nmol/ml (Misselwitz et al. 2002), 
2.20 nmol/ml (A Ahmed et al., 2007) by ELISA and 2.90 nmol/ml (Lieuw et al., 
2004) by LC/MS/MS. Our results showed the mean plasma CML concentration to 
be ~ 1.4 nmol/ml (27.6 pmol/mg) for normal controls, and ~ 2.1 nmol/ml (42.7 
pmol/mg) for AMD patients. For the five diabetic AMD patients, the mean CML 
concentration was ~ 1.5 nmol/ml (32.7 pmol/mg) (Table 4.1). Plasma pentosidine 
concentrations in diabetic patients have been reported to be 90.2 pmol/ml 
(Yamamoto et al., 2008) and 169.7 pmol/ml (Yoshida et al., 2005) by ELISA and 
5.0 pmol/mg by HPLC (Odetti et al., 1992). Our results showed the mean plasma 
pentosidine concentration to be ~ 46.8 pmol/ml (0.95 pmol/mg) for normal 
controls, and ~ 79.5 pmol/ml (1.65 pmol/mg) for AMD patients. For the five 
diabetic AMD patients, the mean pentosidine concentration was ~ 81.6 pmol/ml 
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(1.7 pmol/mg) (Table 4.1). Our results suggest that diabetes had no inflationary 
impact on the CML concentration in AMD patients, and the minimal positive 
impact on the pentosidine concentration was not statistically significant (p-value ~ 
0.8, two sided t-Test). 
 
 
 
          Because diabetes mellitus is a very prevalent disease affecting ~ 200 
million people worldwide, including 20 million in the USA (Mohamed et al., 2007), 
it was important to determined if the observed elevation of CML and pentosidine 
in AMD patients was due to undiagnosed diabetes. To address this issue we 
measured plasma protein furosine because furosine has been used elsewhere to 
Table 4.1. Comparison of CML and Pentosidine from Diabetic and 
Nondiabetic AMD and Control Plasma Donors  
 CML Pentosidine 
 Mean ± SD Mean ± SD 
 
n 
nmol/ml pmol/mg pmol/ml pmol/mg 
Control 
Nondiabetics 30 1.37 ± 0.53 27.6 ± 10.1 46.8 ± 7.0 0.95 ± 0.15
AMD 
Nondiabetics 55 2.11 ± 0.70 43.6 ± 14.9 79.3 ± 23.1 1.64 ± 0.52
AMD 
Diabetics 5 1.54 ± 0.49 32.7 ± 11.2 81.6 ± 25.4 1.73 ± 0.61
CML and pentosidine quantified by LC-MS and LC-fluorimetry from control (n 
= 30) and AMD (n = 60) plasma donors, including non-diabetes (n = 55) and 
diabetes (n = 5) are shown with mean results ± standard deviation (SD). 
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predict the progression of diabetic complications (Monnier et al., 2005). The 
results showed that in our study group AMD patients without diabetes exhibited 
the same mean furosine concentration as normal controls. Notably the five AMD 
patients with diabetes exhibited ~ 20% higher furosine concentration compared 
with the normal controls. The furosine results suggest that there were no 
unknown diabetic patients in our study population. Accordingly, the CML and 
pentosidine plasma levels in AMD patients appear elevated because of AMD 
pathology rather than diabetes.  
          Previous studies have also shown that CML and pentosidine accumulate in 
kidney disorders. For example, in hemodialysis patients, plasma concentrations 
of CML have been reported to be 8.32 nmol/ml (Busch et al., 2004) and 121.4 
pmol/mg (Wagner et al., 2006) by ELISA, and in end-stage renal disease patients 
to be 4.52 nmol/ml by ELISA (Misselwitz et al., 2002). Patients with kidney 
disorders appear to exhibit 2-3 times higher plasma CML concentrations than 
AMD patients. In hemodialysis patients, plasma concentrations of pentosidine 
have been reported to be 1.58 nmol/ml (Busch et al., 2004) and 15.0 - 25.4 
pmol/mg (Jadoul et al., 1999) by HPLC, and in uremic, non-diabetic subjects to 
be 23.7 - 24.7 pmol/mg by HPLC (Odetti et al., 1992; Odetti et al., 1995). 
Patients with kidney disorders appear to exhibit 14 - 20 times higher plasma 
pentosidine concentrations than AMD patients. With regard to AGEs plasma 
levels, kidney disorders and AMD are easily differentiated based on the relatively 
large difference in CML and pentosidine concentrations. 
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          Patients with rheumatoid arthritis have also been reported to have plasma 
pentosidine concentrations of 152 pmol/ml (Chen et al., 1999) and 155 pmol/ml 
(Senolt et al., 2007) by HPLC, which is about 2 times higher than plasma 
pentosidine concentrations in AMD. Although plasma levels of CML and 
pentosidine are elevated in diseases other than AMD, the different scales of 
elevation, the different clinical symptoms of the diseases, and the availability of 
quantitative furosine assays will allow CML and pentosidine to be useful for 
monitoring AMD susceptibility. 
 
4.2 Conclusions 
          Taken together, this study supports the potential utility of plasma protein-
bound CML and pentosidine as biomarkers for predicting AMD susceptibility, 
particularly in combination with CEP biomarkers. The statistical analyses suggest 
that in combination, these biomarkers can discriminate between AMD and control 
donors with up to ~ 95% accuracy. Further optimization of the assay could 
decrease analysis time and improve efficiency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 116
REFERENCES 
 
 
 
A Ahmed K, Muniandy S, S Ismail I. (2007) Role of Nε-(carboxymethyl)lysine in 
the development of ischemic heart disease in type 2 diabetes mellitus. J Clin 
Biochem Nutr. 41(2):97-105. 
 
Age-Related Eye Disease Study Group (AREDS Group) (2000) Risk factors 
associated with age-related macular degeneration. A case-control study in the 
age-related eye disease study: Age-related eye disease study report number 3. 
Ophthalmology 107(12):2224-32. 
 
Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. (1997)         
Nε-(Carboxyethyl)lysine, a product of the chemical modification of proteins by 
methylglyoxal, increases with age in human lens proteins. Biochem J 324:565-70. 
 
 117
Asano M, Fujita Y, Ueda Y, Suzuki D, Miyata T, Sakai H, Saito A. (2002) Renal 
proximal tubular metabolism of protein-linked pentosidine, an advanced glycation 
end product. Nephron. 91(4):688-94. 
 
Baehr W, Wu SM, Bird AC, and Palczewski K. (2003) The retinoid cycle and 
retina disease. Vis Res 43(28):2957-2958. 
 
Ban Y, Rizzolo LJ. (2000) Regulation of glucose transporters during development 
of the retinal pigment epithelium. Brain Res 121:89-95. 
 
Beatty S, Koh H, Phil M, Henson D, Boulton M. (2000) The role of oxidative 
stress in the pathogenesis of age-related macular degeneration. Surv 
Ophthalmol 45(2):115-134. 
 
Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME. (2001) Macular 
pigment and risk for age-related macular degeneration in subjects from a 
Northern European population. Invest Ophthalmol Vis Sci 42:439-446. 
 
Besch D, Jägle H, Scholl HP, Seeliger MW, Zrenner E. (2003) Inherited 
multifocal RPE-diseases: mechanisms for local dysfunction in global retinoid 
cycle gene defects. Vis Res 43(28):3095-3108. 
 
 118
Bird AC. (1992) Pathophysiology of AMD. Editors: Hampton CR, Nelson PT. 
Age-Related Macular degeneration: Principles and Practice. Raven Press, New 
York, p 63-83. 
 
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Klein R, et al. (1995) An 
international classification and grading system for age-related maculopathy and 
agerelated macular degeneration. The International ARM Epidemiological Study 
Group. Surv. Ophthalmol. 39(5):367-374. 
 
Bok D. (1993) The retinal pigment epithelium: a versatile partner in vision. J Cell 
Sci Suppl 17:189-195.  
 
Boulton M, Dayhaw-Barker P. (2001a) The role of the retinal pigment epithelium: 
topographical variation and ageing changes. Eye 15 (Pt 3):384-389. 
 
Brownlee M, Cerami A, Vlassara H. (1988) Advanced glycosylation endproducts 
in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 
318:1315-1321. 
 
Brownlee M. (1995) Advanced protein glycosylation in diabetes and aging. Ann 
Rev Med. 46:223-234. 
 
 119
Bucala R, Cerami A. (1992) Advanced glycation: chemistry, biology and 
implications for diabetes and aging. Adv Pharmacol. 23:1-34. 
 
Bucala R. (1997) Lipid and lipoprotein modification by AGE’s: role in 
atherosclerosis. Exp Physiol. 82:327-337. 
 
Busch M, Franke S, Müller A, Wolf M, Gerth J, Niwa T, Stein G. (2004) Potential 
cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine 
and metabolites, and the C-reactive protein. Kidney Int. 66(1):338-47. 
 
Chan D. (1998) Cigarette smoking and age-related macular degeneration. Optom 
Vis Sci 75:476-484. 
 
Chaplen FW, Fahl WE, Cameron DC. (1998) Evidence of high levels of 
methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 
95(10):5533-5538. 
 
Chen JR, Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T. (1999) 
Comparison of the concentrations of pentosidine in the synovial fluid, serum and 
urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology 
(Oxford). 38(12):1275-8. 
 
 120
Cohen S, DeAntonis K, Michaud DP. (1993) Compositional protein analysis using 
6-aminoquinolyl-n-hydroxysuccinimidyl carbamate, a novel derivatising agent, in 
Techniques in Protein Chemistry IV (Angeletti R., ed.) Academic, San Diego, CA. 
289-306. 
 
Crabb JW, West KA, Dodson WS, Hulmes JD. (1997) Amino Acid Analysis. In: 
Current Protocols in Protein Science (J.E. Coligan, H.L. Ploegh, J.A. Smith and 
D.W. Speicher, eds.) Unit 11.9 (Supplement 7) John Wiley & Sons, Inc., 
Hoboken NJ, pages 11.9.1-11.9.42. 
 
Crabb JW, Miyagi M, Gu X, Rayborn ME, Salomon RG, Hollyfield JG, et al. (2002) 
Drusen proteome analysis: an approach to the etiology of age-related macular  
degeneration. Proc Natl Acad Sci U S A 99(23):14682-14687. 
 
Cruickshanks KJ, Klein R, Klein BE. (1993) Sunlight and age-related macular 
degeneration. The Beaver Dam Eye Study. Arch Ophthalmol 111:514-518. 
 
Dalle-Donne I, Rossi R, Colombo R, Giustarini D, and Milzani A. (2006) 
Biomarkers of oxidative damage in human disease. Clin Chem 52(4): 601-623. 
 
Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Heymes C, et al. (2004) 
Increased neuronal nitric oxide synthase-derived NO production in the failing 
human heart. Lancet 363(9418):1365-1367. 
 121
 
de Jong PT. (2006) Mechanism of disease Age-Related Macular Degeneration. 
N Engl J Med 355:1474-85. 
 
Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L. (1998) Smoking and age-
related macular degeneration. The POLA Study. Pathologies Oculaires Liées à 
l'Age. Arch Ophthalmol 116:1031-5.  
 
Dornonville de la Cour M. (1993) Ion transport in the retinal pigment epithelium. A 
study with double barrelled ion-selective microelectrodes. Acta Ophthalmol Suppl. 
209:1-32. 
 
Ebrahem Q, Renganathan K, Salomon RG, Crabb JW, Anand-Apte B. (2006) 
Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: 
Implications for age-related macular degeneration. Proc Natl Acad Sci. 103 
(36):13480-4. 
 
Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. (2005) 
Complement factor H polymorphism and age-related macular degeneration. 
Science 308, 421-424. 
 
Eye Disease Case-Control (EDCC) Study Group. (1993) Antioxidant status and 
neovascular age-related macular degeneration. Arch Ophthalmol. 111: 104-9. 
 122
 
Feeney-Burns L, Ellersieck MR. (1985) Age-related changes in the ultrastructure 
of Bruch’s membrane. Amer J Ophthalmol.100:686-97. 
 
Finnemann SC. (2003) Focal adhesion kinase signaling promotes phagocytosis 
of integrin-bound photoreceptors. EMBO J 22:4143-4154. 
 
Fliesler SJ, Anderson RE. (1983) Chemistry and metabolism of lipids in the 
vertebrate retina. Prog Lipid Res. 22:79-131. 
 
Floridi A, Antolini F, Galli F, Fagugli RM, et al. (1998) Daily haemodialysis 
improves indices of protein glycation. Nephrol Dial Transplant 17:871-878. 
 
Forrester J, Dick A, McMeanamin P, Lee W (1996). The eye: basic sciences in 
practice (W. B. Saunders Company Ltd, London). 
 
Frank A, Sell DR, Danielsson R, Fogarty JF, Monnier VM. (2000) A syndrome of 
molybdenosis, copper deficiency, and type 2 diabetes in the moose population of 
south-west Sweden.  Sci Total Environ. 249:123-131. 
 
Frank RN, Amin RH, Puklin JE. (1999) Antioxidant enzymes in the macular 
retinal pigment epithelium of eyes with neovascular age-related macular 
degeneration. Am J Ophthalmol 127:694-709. 
 123
 
Frei B, England L, Ames BN. (1989) Ascorbate is an outstanding antioxidant in 
human blood plasma. Proc Natl Acad Sci. 86: 6377-81. 
 
Friedlander MA, Wu YC, Elgawish A, Monnier VM. (1996) Early and advanced 
glycosylation end products. Kinetics of formation and clearance in peritoneal 
dialysis. J Clin Invest. 97(3):728-35. 
 
Friedman DS, Katz J, Bressler NM, et al. (1999) Racial differences in the 
prevalence of age-related macular degeneration: the Baltimore Eye Survey. 
Ophthalmology 106:1049-55.  
 
Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, et al. (2004) 
Prevalence of age-related macular degeneration in the United States. Arch 
Ophthalmol 122:564-72. 
 
Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. (1996) The 
advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both 
lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-6. 
 
Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, Vollrath D. (2000) 
Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy 
gene, cause retinitis pigmentosa. Nat Genet 26:270-271.  
 124
 
Genuth S, Sun W, Sell DR, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary 
Study Group. (2005) Glycation and carboxymethyllysine levels in skin collagen 
predict the risk of future 10-year progression of diabetic retinopathy and 
nephropathy in the diabetes control and complications trial and epidemiology of 
diabetes interventions and complications participants with type 1 diabetes. 
Diabetes. 54(11):3103-11. 
 
Glenn JV, Beattie JR, Barrett L, et al. (2007) Confocal Raman microscopy can 
quantify advanced glycation end product (AGE) modifications in Bruch’s 
membrane leading to accurate, nondestructive prediction of ocular aging. FASEB 
J. 21(13):3542-3552. 
 
Glenn JV, Mahaffy H, Wu K, Simpson DA, Stitt AW, et al. (2009) Advanced 
glycation end product (AGE) accumulation on Bruch's membrane: links to age-
related RPE dysfunction. Invest Ophthalmol Vis Sci. 50(1):441-51. 
 
Glomb MA, Pfahler C. (2001) Amides are novel protein modifications formed by 
physiological sugars. J Biol Chem. 276:41638-41647. 
 
Goh SY, Cooper ME. (2008) Clinical review: The role of advanced glycation end 
products in progression and complications of diabetes. J Clin Endocrinol Metab. 
93(4):1143-52. 
 125
 
Gold B, Merriam JE, Zernant J, Hageman GS, Allikmets R, et al. (2006) Variation 
in factor B (BF) and complement component 2 (C2) genes is associated with 
age-related macular degeneration. Nat. Genet. 38, 458-462. 
 
Gragoudas ES, Adamis AP, Cunningham ET. (2004) Pegaptanib for neovascular 
age-related macular degeneration. N Engl J Med 351:2805-16. 
 
Green WR, McDonnel PJ, Yeo JH. (1985) Pathologic features of senile macular 
degeneration. Ophthalmology 92:615-627. 
 
Gu J, Pauer G, Gu X, Crabb JW, et al. (2009) Predicting susceptibility to age-
related macular degeneration with proteomic and genomic biomarkers. Molecular 
and Cellular Proteomics-In press. 
 
Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, et al. (2003) 
Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-
related macular degeneration. J. Biol. Chem. 278: 42027-35. 
 
Gu X, Renganathan K, Grimm C, Wenzel A, Salomon RG, Crabb JW, et al. 
(2004) Rapid Changes in Retinal Oxidative Protein Modificatins Induced by Blue 
Light. Invest Ophthalmol Vis Sci. 45:E-abstract 3474. 
 
 126
Hageman GS, Mullins RF. (1999) Molecular composition of drusens as related to 
substructural phenotype. Mol Vis.5:28. 
 
Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Mulins RF, et al. (2001) 
An integrated hypothesis that considers drusen as biomarkers of immune-
mediated processes at the RPEBruch’s membrane interface in aging and age-
related macular degeneration. Prog Retin Eye Res 20:705-732. 
 
Hageman GS, Anderson DH, Johnson LV, Hageman JL, Allikmets R, et al. (2005) 
A common haplotype in the complement regulatory gene factor H (HF1/CFH) 
predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. 
Sci. U.S.A. 102, 7227-7232. 
 
Hageman GS, Hancox LS, Taiber AJ, Allikmets R, Dean M, Group ACS, et al. 
(2006) Extended haplotypes in the complement factor H (CFH) and CFH-related 
(CFHR) family of genes protect against age-related macular degeneration: 
characterization, ethnic distribution and evolutionary implications. Ann. Med. 38, 
592-604. 
 
Haik GM, Lo TW, Thornalley PJ. (1994) Methylglyoxal concentration and 
glyoxalase activities in the human lens. Exp. Eye Res. 59, 497-500. 
 
 127
Haines JL, Hauser MA, Schmidt KL, Kwan SY, Postel EA, et al. (2005) 
Complement factor H variant increases the risk of age-related macular 
degeneration. Science 308, 419-421. 
 
Hamann S, la Cour M, Lui GM, Bundgaard M, Zeuthen T. (2000) Transport of 
protons and lactate in cultured human fetal retinal pigment epithelial cells. 
Pflϋgers Arch 440:84-92. 
 
Handa JT, Verzijl N, Matsunaga H, Lutty GA, Hjelmeland LM, et al. (1999) 
Increase in the advanced glycation end product pentosidine in Bruch’s 
membrane with age. Invest. Ophthalmol. Vis. Sci. 40(3):775-779. 
 
Heidland A, Sebeková K, Frangiosa A, Schinzel R, et al. (2004) Paradox of 
circulating advanced glycation end product concentrations in patients with 
congestive heart failure and after heart transplantation. Heart 90(11):1269-74.  
 
Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P. (2002) 
Advanced glycation end products induce choroidal endothelial cell proliferation, 
matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin 
Exp Ophthalmol. 240(12):996-1002. 
 
 128
Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Lu L, Salomon RG, et al. (2008) 
Oxidative damage-induced inflammation initiates age-related macular 
degeneration. Nat Med. 14(2):194-8. 
 
Holz FG, Sheraidah G, Pauleikhoff D, et al. (1994) Analysis of lipid deposits 
extracted from human macular and peripheral Bruch’s membrane. Arch 
Ophthalmol. 112:402-6. 
 
Horie K, Miyata T, Maeda K, Miyata S, Monnier VM, Kurokawa K, et al. (1997) 
Immunohistochemical colocalization of glycoxidation products and lipid 
peroxidation products in diabetic renal glomerular lesions. Implication for 
glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 
100(12):2995-3004. 
 
Howes KA, Liu Y, Dunaief JL, Milam A, Marks A, Baehr W, et al. (2004) Receptor 
for advanced glycation end products and age-related macular degeneration. 
Invest. Ophthalmol. Vis. Sci. 45(10):3713-3720. 
 
Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. (1983) Senile macular 
degeneration: a case-control study. Am J Epidemiol 118:213-27. 
 
 129
Ishibashi T, Murata T, Hangai M, Nagai R, Ryan SJ, et al. (1998) Advanced 
glycation end products in age-related macular degeneration. Arch Ophthalmol. 
116(12):1629-32.  
 
Ishida K, Panjwani N, Cao Z, and Streilein JW. (2003) Participation of pigment 
epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, 
and retina suppress T-cell activation  by partially non-overlapping mechanisms. 
Ocul Immunol Inflamm 11(2):91-105. 
 
Jadoul M, Ueda Y, Yasuda Y, Ishida N, Kurokawa K, Miyata T, et al. (1999) 
Influence of hemodialysis membrane type on pentosidine plasma level, a marker 
of "carbonyl stress". Kidney Int. 55(6):2487-92. 
 
Jager RD, Mieler WF, Miller JW. (2008) Age-related macular degeneration. N 
Engl J Med 358:2606-17. 
 
Johnson LV, Anderson DH. (2004) Age-related macular degeneration and the 
extracellular matrix. N Engl J Med. 351(4):320-2. 
 
Jump DB. (2002) The biochemistry of n-3 polyunsaturated fatty acids. J Biol 
Chem. 277:8755-8758. 
 
 130
Kaur K, Salomon RG, O'Neil J, Hoff HF. (1997) (Carboxyalkyl)pyrroles in human 
plasma and oxidized low-density lipoproteins. Chem Res Toxicol. 10:1387-96. 
 
Kayatz P, Thumann G, Luther TT, et al. (2001) Oxidation causes melanin 
fluorescence. Invest Ophthalmol Vis Sci 42:241-6.  
 
Kennedy CJ, Rakoczy PE, Constable IJ. (1995) Lipofuscin of the retinal pigment 
epithelium: a review. EYE 9:763-771. 
 
Kitauchi T, et al. (2004) Association between pentosidine and arteriosclerosis in 
patients receiving hemodialysis. Clin. Exp. Nephrol. 8:48-53.  
 
Klaver ED, Wolfs RC, Vingerling JR, Hoffman A, de Jong PT. (1998) Age-specific 
prevalence and causes of blindness and visual impairment in an older population: 
the Rotterdam Study. Arch Ophthalmol. 116:653-8. 
 
Klein R, Klein BE, Marino EK, et al. (2003) Early age-related maculopathy in the 
cardiovascular health study. Ophthalmology 110:25-33.  
 
Klein R, Klein BE, Moss SE. (1998) Relation of smoking to the incidence of age-
related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 147:103-10.  
 
 131
Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. (2002) Ten-year 
incidence and progression of age-related maculopathy: The Beaver Dam eye 
study. Ophthalmology 109(10):1767-1779. 
 
Klein RJ, Zeiss C, Chew EY, Henning AK, Ott J, Barnstable C, Hoh J, et al. 
(2005) Complement factor H polymorphism in age-related macular degeneration. 
Science 308, 385-389. 
 
Krajcovicová-Kudlácková M, Sebeková K, Schinzel R, et al. (2002) Advanced 
Glycation End Products and Nutrition. Physiol Res. 51(3):313-6. 
 
Krause R, Knoll K, Henle T. (2003) Studies on the formation of furosine and 
pyridosine during acid hydrolysis of different Amadori products of lysine. Eur 
Food Res Technol. 216:277-283. 
 
Krinsky NI, Deneke SM. (1982) Interaction of oxygen and oxy-radicals with 
carotenoids. J Natl Cancer Inst 69: 205-10. 
 
Landrum JT, Bone RA, Moore LL, Gomez CM. (1999) Analysis of zeaxanthin 
distribution within individual human retinas. Methods Enzymol 299: 457-467. 
 
Lee AT, Cerami A. (1992) Role of glycation in aging. Ann NY Acad Sci. 663:63-
70. 
 132
 
Liang FQ, Godley BF, et al. (2003) Oxidative stress-induced mitochondrial DNA 
damage in human retinal pigment epithelial cells: a possible mechanism for RPE 
aging and age-related macular degeneration. Exp Eye Res. Apr; 76(4):397-403. 
 
Lieuw-A-Fa ML, van Hinsbergh VW, Stehouwer CD, Schalkwijk CG, et al. (2004) 
Increased levels of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine in type 
1 diabetic patients with impaired renal function: correlation with markers of 
endothelial dysfunction. Nephrol Dial Transplant. 19(3):631-6. 
 
Lu M, Kuroki M, Amano S, et al. (1998) Advanced glycation end products 
increase retinal vascular endothelial growth factor expression. J Clin Invest. 
101:1219-1224. 
 
Maillard LC. (1912) Action des acides amines sur les sucres: formation des 
malaniodines par voie methodique. Compte-Rendu de l’Acade´mie des Sciences 
154:66-68. 
 
Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, et al. (1994) 
Reactive glycosylation endproducts in diabetic uraemia and treatment of renal 
failure. Lancet. 343(8912):1519-22. 
 
 133
Makita Z, Vlassara H, Cerami A, and Bucala R. (1992) Immunochemical 
detection of advanced glycosylation endproducts in vivo. J. Biol. Chem. 
267:5133-5138. 
 
Marmor MF. (1999) Mechanisms of fluid accumulation in retinal edema. Doc 
Ophthalmol 97(3-4):239-249. 
 
Marmorstein AD, Finnemann SC, Bonilha VL, Rodriguez-Boulan E. (1998) 
Morphogenesis of the retinal pigment epithelium: toward understanding retinal 
degenerative diseases. Ann NY Acad Sci 857:1-12. 
 
McBee JK, Palczewski K, Baehr W, Pepperberg DR. (2001) Confronting 
complexity: the interlink of phototransduction and retinoid metabolism in the 
vertebrate retina. Prog Retin Eye Res 20:469-529. 
 
McCance DR, Dyer DG, Dunn JA, Baynes JW, et al. (1993) Maillard reaction 
products and their relation to complications in insulin-dependent diabetes mellitus. 
J. Clin. Invest. 91:2470-2478. 
 
Meyers SM. (1994) A twin study on age-related macular degeneration. Trans Am 
Ophthalmol Soc. 92:775-843. 
 
 134
Miceli MV, Liles MR, Newsome DA. (1994) Evaluation of oxidative processes in 
human pigment epithelial cells associated with retinal outer segment 
phagocytosis. Exp Cell Res 214:242-249. 
 
Miller SS, Edelman JL. (1990) Active ion transport pathways in the bovine retinal 
pigment epithelium. J Physiol 424:283-300. 
 
Misselwitz J, Franke S, Kauf E, John U, Stein G. (2002) Advanced glycation end 
products in children with chronic renal failure and type 1 diabetes. Pediatr 
Nephrol. 17(5):316-21. 
 
Mitchell P, Wang JJ, Foran S, Smith W. (2002a) Five-year incidence of age-
related maculopathy lesions: The Blue Mountains eye study. Ophthalmology 
109:1092-7.  
 
Mitchell P, Wang JJ, Smith W, Leeder SR. (2002b) Smoking and the 5-year 
incidence of age-related maculopathy: the Blue Mountains Eye Study. Arch 
Ophthalmol 120:1357-63.  
 
Miura J, Yamagishi S, Uchigata Y, Makita Z, et al. (2003) Serum levels of non-
carboxymethyllysine advanced glycation endproducts are correlated to severity 
of microvascular complications in patients with type 1 diabetes. J. Diabetes 
Complications 17:16-21.  
 135
 
Miyata T, Ueda Y, Yoshida A, Jadoul M, Maeda K, Kurokawa K, et al. (1997) 
Clearance of pentosidine, an advanced glycation end product, by different 
modalities of renal replacement therapy. Kidney Int. 51(3):880-7. 
 
Miyata T, Fu MX, Kurokawa K, van Ypersele dS, Thorpe SR, Baynes JW. (1998) 
Autoxidation products of both carbohydrates and lipids are increased in uremic 
plasma: is there oxidative stress in uremia? Kidney Int. 54:1290-1295. 
 
Mohamed Q, Gillies MC, Wong TY. (2007) Management of diabetic retinopathy: 
a systematic review. JAMA. 298(8):902-16. 
 
Monnier VM, Vishwanatha V, Frank KE, Kohn RR, et al. (1986) Relation between 
complications of type 1 diabetes mellitus and collagen-linked fluorescence. N. 
Engl. J. Med. 314:403-408. 
 
Monnier VM, Sell DR, Nagaraj RH, Miyata S, Odetti P, et al. (1992) Maillard 
reaction-mediated molecular damage to extracellular matrix and other tissue 
proteins in diabetes, aging, and uremia. Diabetes 41(Suppl 2):36-41. 
 
Monnier VM, Sell DR, Genuth S. (2005) Glycation products as markers and 
predictors of the progression of diabetic complications. Ann N Y Acad Sci. 
1043:567-81. 
 136
 
Nagai R, Ikeda K, Higashi T, et al. (1997) Hydroxyl radical mediates                 
Nε-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res 
Commun. 234:167-172. 
 
Newsome DA, Miceli MV, Liles M, Tate D, Oliver PD. (1994) Antioxidants in the 
retinal pigment epithelium. Prog Retin Eye Res. 13:101-123. 
 
Ng KP, Gugiu B, Renganathan K, Gu X, Hollyfield JG, Crabb JW, et al. (2008) 
Retinal pigment epithelium lipofuscin proteomics. Mol Cell Proteomics. 
7(7):1397-405. 
 
Niwa T. (2006) Mass spectrometry for the study of protein glycation in disease. 
Mass Spectrom Rev. 25(5):713– 723. 
 
Odetti P, Fogarty J, Sell DR, Monnier VM. (1992) Chromatographic quantitation 
of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes. 
41(2):153-9. 
 
Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G. (1995) Plasma advanced 
glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial 
Transplant. 10(11):2110-3. 
 
 137
Odetti P, Rossi S, Monacelli F, Federici A, et al. (2005) Advanced glycation end 
products and bone loss during aging. Ann N Y Acad Sci. 1043:710-7. 
 
Okubo A, Rosa RH Jr, Bunce CV, Bird AC, Luthert PJ, et al. (1999) The 
relationships of age changes in retinal pigment epithelium and Bruch’s 
membrane. Invest. Ophthalmol. Vis. Sci. 40(2):443-449. 
 
Oliver PD, Newsome DA. (1992) Mitochondrial superoxide dismutase in mature 
and developing human retinal pigment epithelium. Invest Ophthalmol Vis Sci 
33:1909-1918. 
 
Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, Uchida K. (1999) 
Methylglyoxal modification of protein: chemical and immunochemical 
characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274:18492-
18502. 
 
Packer L, Landvik S. (1990) Vitamin E in biological systems. Adv Exp Med Biol. 
264: 93-103. 
 
Packer L. (1993) Antioxidant action of carotenoids in vitro and in vivo and 
protection against oxidation of human low-density lipoproteins. Ann N Y Acad Sci. 
691: 48-60. 
 
 138
Pesek JJ, Matyska MT, Fischer SM, Sana TR, et al. (2008) Analysis of 
hydrophilic metabolites by high-performance liquid chromatography-mass 
spectrometry using a silica hydride-based stationary phase. Journal of 
Chromatography A. 1204: 48-55. 
 
Phillips SA, and Thornalley PJ. (1993) Formation of methylglyoxal and D-lactate 
in human red blood cells in vitro. Biochem. Soc. Trans. 21, 163S. 
 
Pieramici DJ, Bressler NM, Bressler SB, Schachat AP. (1994) Choroidal 
neovascularization in black patients. Arch Ophthalmol 112:1043-6.  
 
Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, et al. (2002) Identification of a 
novel family of oxidized phospholipids that serve as ligands for the macrophage 
scavenger receptor CD36. J Biol Chem. 277:38503-16. 
 
Raj DS, Lim G, Levi M, Qualls C, Jain SK. (2004) Advanced glycation end 
products and oxidative stress are increased in chronic allograft nephropathy. Am 
J Kidney Dis. 43(1):154-60. 
 
Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. (1995)                      
Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) 
antigen in tissue proteins. Biochemistry. 34:10872-10878. 
 
 139
Renganathan K, Sun M, Gu X, Salomon RG, Hazen S, Crabb JW, et al. (2003) 
Light Induced Protein Modifications and Lipid Oxidation Products in Rat Retina. 
Invest Ophthalmol Vis Sci. 44:E-abstract 5129. 
 
Rivera A, Fisher SA, Lichtner P, Meitinger T, Weber BHF, et al. (2005) 
Hypothetical LOC387715 is a second major susceptibility gene for age-related 
macular degeneration, contributing independently of complement factor H to 
disease risk. Hum. Mol. Genet. 14, 3227-3236. 
 
Riviere S, Birlouez-Aragon I, Vellas B. (1998) Plasma protein glycation in 
Alzheimer’s disease. Glycoconj J. 15:1039-1042.  
 
Rose RC, Richer SP, Bode AM. (1998) Ocular oxidants and antioxidant 
protection. Proc Soc Exp Boil Med 217:397-407. 
 
Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. (2006) Tolerability and 
efficacy of multiple escalating doses of ranibizumab (Leucentis) for neovascular 
age-related macular degeneration. Ophthalmology 113(4):632. el. 
 
Rozanowska M, Jarvis-Evans J, Korytowski W, Sarna T, et al. (1995) Blue light-
induced reactivity of retinal age pigment, in vitro generation of oxygen-reactive 
species. J Biol Chem 270:18825-30. 
 
 140
Ryan SJ, Stout JT, Dugel PU. (1994) Subretinal neovascularization. In: Ryan SJ, 
ed. Retina. St Louis, Mo: Mosby-Year Book Inc:1027-1047. 
 
Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP. (1999) Early drusen formation 
in the normal and aging eye and their relation to age related maculopathy: a 
clinicopathological study. Br J Ophthalmol; 83:358-68. 
 
Schmidt AM, Yan SD, Yan SF, Stern DM. (2001) The multiligand receptor RAGE 
as a progression factor amplifying immune and inflammatory responses. J. Clin. 
Invest. 108 (7), 949-955. 
 
Schmidt-Erfurth U. (2005) Nutrition and retina. Dev Ophthalmol 38:120-147. 
 
Scholl HP, Fleckenstein M, Keilhauer C, Holz FG, Weber BH, et al. (2007) An 
update on the genetics of age-related macular degeneration. Mol. Vis. 13, 196-
205. 
 
Sebeková K, Podracká L, Heidland A, Schinzel R, et al. (2001) Plasma levels of 
advanced glycation end products in children with renal disease. Pediatr Nephrol. 
16(12):1105-12.  
 
 141
Seddon JM, Willett WC, Speizer FE, Hankinson SE. (1996) A prospective study 
of cigarette smoking and age-related macular degeneration in women. J Am Med 
Assoc 276:1141-1146. 
 
Sell DR, Monnier VM. (1989) Structure elucidation of a senescence cross-link 
from human extracellular matrix. Implication of pentoses in the aging process. J 
Biol Chem 264(36):21597-602. 
 
Sell DR, Monnier VM. (1990) End-stage renal disease and diabetes catalyze the 
formation of a pentose-derived crosslink from aging human collagen. J Clin 
Invest. 85:380-384. 
 
Senolt L, Braun M, Vencovský J, Sedová L, Pavelka K. (2007) Advanced 
glycation end-product pentosidine is not a relevant marker of disease activity in 
patients with rheumatoid arthritis. Physiol Res. 56(6):771-7. 
 
Shaw JN, Baynes JW, Thorpe SR. (2002) Nε-(carboxymethyl)lysine (CML) as a 
biomarker of oxidative stress in long-lived tissue proteins. Methods Mol Biol. 
186:129-37. 
 
Shen JK, Dong A, Hackett SF, Bell WR, Green WR, and Campochiaro PA. (2007) 
Oxidative damage in age-related macular degeneration. Histol Histopathol 
22(12):1301-1308. 
 142
 
Singh R, Barden A, Mori T, Beilin L. (2001) Advanced glycation endproducts: a 
review. Diabetologia. 44:129-146. 
 
Słowik-Zyłka D, Safranow K, Dziedziejko V, Chlubek D, et al. (2004) A sensitive 
and specific HPLC method for the determination of total pentosidine 
concentration in plasma. J Biochem Biophys Methods. 61(3):313-29. 
 
Smith W, Mitchell P, Leeder SR. (1996) Smoking and age-related maculopathy. 
The Blue Mountains Eye Study. Arch Ophthalmol 114:1518-23.  
 
Smith W, Assink J, Klein R, et al. (2001) Risk factors for age-related macular 
degeneration: pooled findings from three continents. Ophthalmology 108:697-704.  
 
Snodderly DM. (1995) Evidence for protection against age-related macular 
degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr Suppl 
62:1148s-1161s. 
 
Sparrow JR, Nakanishi K, Parish CA. (2000) The lipofuscin fluorophore A2E 
mediates blue light-induced damage to retinal pigmented epithelial cells. Invest 
Ophthalmol Vis Sci 41: 1981-1989. 
 
 143
Spraul CW, Lang GE, Grossniklaus HE. (1996) Morphometric analysis of the 
choroid, Bruch’s membrane and retinal pigment epithelium in eyes with age-
related macular degeneration. Invest Ophthalmol Vis Sci 37:2724-35. 
 
Starita C, Hussein AA, Patmore A, Marshall J. (1997) Localization of the site of 
major resistence to fluid transport in Bruch’s membrane. Invest Ophthamol Vis 
Sci.38:762-7. 
 
Steinberg RH, Linsenmeier RA, and Griff ER. (1983) Three lightevoked 
responses of the retinal pigment epithelium. Vision Res 23:1315-1323. 
 
Steinberg RH. (1985) Interactions between the retinal pigment epithelium and the 
neural retina. Doc Ophthalmol 60:327-346.  
 
Strauss O, Stumpff F, Mergler S, Wienrich M, and Wiederholt M. (1998) The 
Royal College of Surgeons rat: an animal model for inherited retinal degeneration 
with a still unknown genetic defect. Acta Anat 162:101-111. 
 
Strauss O. (2005) The retinal pigment epithelium in visual function. Physiol. Rev. 
85(3):845-881. 
 
 144
Streilein JW, Ma N, Wenkel H, Ng TF, Zamiri P. (2002) Immunobiology and 
privilege of neuronal retina and pigment epithelium transplants. Vision Res 
42:487-495. 
 
Subbanagounder G, Deng Y, Borromeo C, Dooley AN, Berliner JA, et al. (2002) 
Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial 
cells. Vascul Pharmacol. 38:201-9. 
 
Sun M, Deng Y, Batyreva E, Sha W, Salomon RG. (2002) Novel bioactive 
phospholipids: practical total syntheses of products from the oxidation of 
arachidonic and linoleic esters of 2-lysophosphatidylcholine(1). J Org Chem. 
67:3575-84. 
 
Sundelin SP, Nilsson SE, Brunk UT. (2001) Lipofuscin-formation in cultured 
retinal pigment epithelial cells is related to their melanin content. Free Radic Biol 
Med 30:74-81.  
 
Tate DJ, Miceli MV, Newsome DA. (1995) Phagocytosis and H2O2 induce 
catalase and metallothionein gene expression in human retinal pigment epithelial 
cells. Invest Ophthalmol Vis Sci 36:1271-1279. 
 
Thompson DA, Gal A. (2003) Vitamin A metabolism in the retinal pigment 
epithelium: genes, mutations, and diseases. Prog Retin Eye Res 22:683-703. 
 145
 
Thornalley PJ, Langborg A, Minhas HS. (1999) Formation of glyoxal, 
methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. 
Biochem. J. 344(Pt 1):109-116. 
 
Thornalley PJ, Battah S, Ahmed N, Babaei-Jadidi R, Dawnay A, et al. (2003) 
Quantitative screening of advanced glycation endproducts in cellular and 
extracellular proteins by tandem mass spectrometry. Biochem. J. 375(Pt 3):581–
592. 
 
Thorpe SR, Baynes JW. (2003) Maillard reaction products in tissue proteins: new 
products and new perspectives. Amino Acids 25(3-4):275-281. 
 
Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Pauleikhoff D. (2007) 
Changes in macular pigment optical density and serum concentrations of its 
constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA 
study. Exp Eye Res 84(4):718-728. 
 
Ulrich P, Zhang X. (1997) Pharmacological reversal of AGE-mediated protein 
cross-linking. Diabetologia 40:S157-S159. 
 
 146
van der Hagen AM, Yolton DP, Kaminski MS, Yolton, RL. (1993) Free radicals 
and antioxidants supplementation: a review of their roles in age-related macular 
degeneration. J Am Optom Assoc 64:871-878. 
 
Vlassara H, Li YM, Imani F, Wojciechowicz D, Cerami A. (1995) Identification of 
galectin-3 as a high-affinity binding protein for advanced glycation end products 
(AGE): a new member of the AGE-receptor complex. Mol. Med. 1 (6), 634-646. 
 
Vlassara H. (1996) AGE’s and atherosclerosis. Ann Med. 28:419-426. 
 
Wagner Z, Molnár M, Csiky B, Heidland A, Nagy J, Wittmann I, et al. (2006) 
Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J 
Kidney Dis. 47(2):294-300. 
 
Ward M. (1996) Amino Acid Analysis Using Precolumn Derivatization with 6-
Aminoquinolyl- n -Hydroxysuccinimidyl Carbamate. The Protein Protocols 
Handbook Part V (Walker JM, ed.). Humana Press Inc., Totowa, NJ. 461-465. 
 
Weiss MF, Erhard P, Wu YC, Glomb MA, Monnier VM. (2000) Mechanisms for 
the formation of glycoxidation products in end-stage renal disease. Kidney Int. 
57(6):2571-85. 
 
 147
Wilker SC, Chellan P, Arnold BM, Nagaraj RH. (2001) Chromatographic 
Quantification of Argpyrimidine, a Methylglyoxal-Derived Product in Tissue 
Proteins: Comparison with Pentosidine. Analytical Biochemistry 290, 353-358. 
 
Winkler BS, Boulton ME, Gottsch JD, Sternberg P. (1999) Oxidative damage and 
age-related macular degeneration. Mol Vis 5:32. 
 
Yamada Y, Ishibashi K, Ishibashi K, Bhutto IA, Handa JT, et al. (2006) The 
expression of advanced glycation endproduct receptors in rpe cells associated 
with basal deposits in human maculas. Exp. Eye. Res. 82:840-848. 
 
Yamagishi S, Yonekura H, Yamamoto Y, et al. (1997) Advanced glycation end 
productsdriven angiogenesis in vitro: induction of the growth and tube formation 
of human microvascular endothelial cells through autocrine vascular endothelial 
growth factor. J Biol Chem. 272:8723-8730. 
 
Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. (2008) Serum 
pentosidine levels are positively associated with the presence of vertebral 
fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol 
Metab. 93(3):1013-9. 
 
 148
Yates JR, Sepp T, Matharu BK, Redmond E, Bird AC, Moore AT and the Genetic 
Factors in AMD study group. (2007) Complement C3 variant and the risk of age-
related macular degeneration. N. Engl. J. Med. 357(6), 553-561. 
 
Yoshida N, Okumura K, Aso Y. (2005) High serum pentosidine concentrations 
are associated with increased arterial stiffness and thickness in patients with type 
2 diabetes. Metabolism. 54(3):345-50. 
 
Young RW. (1970) Visual cells. Sci. Am. 223:80-91. 
 
Zarbin MA. (1998) Age-related macular degeneration: review of pathogenesis. 
Eur J Ophthalmol 8:199-206. 
 
Zarbin MA. (2004) Current concepts in the pathogenesis of age-related macular 
degeneration. Arch Ophthalmol. Apr; 122(4):598-614. 
 
